Atypical split inteins and their uses
Atypical split inteins with accelerated splicing rates and improved stability address the limitations of existing inteins, enabling efficient protein ligation and modification applications.
Patent Information
- Application Number
- JP2022513402
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-08-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-08-28
AI Technical Summary
Existing split inteins exhibit slow kinetics, context-dependent efficiency, low expression levels, and suboptimal stability, limiting their practical utility in protein purification and modification applications.
Development of atypical split inteins with accelerated splicing rates and improved activity under adverse conditions, comprising specific amino acid sequences (SEQ ID NOs) for N- and C-terminal fragments, which can be linked via amide bonds or linkers for protein modifications.
The atypical split inteins demonstrate enhanced splicing efficiency and stability, facilitating efficient protein ligation and modification, particularly in challenging environments.
Smart Images

Figure 0007579844000017 
Figure 0007579844000018 
Figure 0007579844000019
Abstract
Description
[Technical field]
[0001] Government Rights in Inventions This invention was made with Government support under Grant Nos. GM086868, OD016305, RR015495 and OD016432 awarded by the National Institutes of Health. The US Government has certain rights in this invention.
[0002] FIELD OF THEINVENTION The present disclosure is in the field of biotechnology, and specifically relates to split inteins and their uses. [Background technology]
[0003] 2. Background of the Invention Inteins are intervening protein domains that undergo a post-translational autoprocessing event called protein splicing, which simultaneously excises itself from the host protein and tracelessly joins its adjacent polypeptide sequences (exteins) to form native peptide bonds. Most inteins are found as continuous domains embedded within a single gene and splice in cis. However, some naturally occur in split form, whereby each intein fragment is encoded in a separately expressed gene and must first assemble before splicing in trans. These split inteins are commonly applied as tools in protein engineering and are particularly amenable to use in cellular environments due to their highly specific recognition and unique activity.
[0004] Despite the increasing use of inteins in chemical biology, their practical utility has been limited by several general characteristics: (i) slow kinetics, (ii) context-dependent efficiency with respect to the immediately adjacent extein sequences, (iii) low expression levels in recombinant fusions with other proteins, and (iv) suboptimal stability.
[0005] Thus, there is a need for more robust and more efficient split inteins for use in a variety of protein purification and protein modification applications. Summary of the Invention
[0006] Summary of the Invention The authors of the present disclosure thereby provide split inteins with atypical split sites that exhibit accelerated splicing rates and activity even under adverse conditions, as shown in Example 1 of the present application (Figure 5, Tables 5 and 6). The disclosed inteins are useful for N-terminal modification of expressed proteins and complement other methods reported for N-terminal modification of proteins, such as ligation of expressed proteins, transpeptidase-based ligation strategies, and various protein chemistry methods. In this regard, the N-terminal intein fragments of these inteins are remarkably short, making the isolated polypeptides ideally suited for use in a range of protein modifications, since composite proteins of the desired split intein N-terminal fragments can be easily obtained using solid-phase peptide synthesis.
[0007] Thus, in one aspect of the disclosure, the invention relates to a split intein N-fragment comprising the amino acid sequence of SEQ ID NO:1 or a variant thereof having at least 90% sequence identity to SEQ ID NO:1.
[0008] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: (i) target compound, (ii) a split intein N-terminal fragment of the present disclosure, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. A complex comprising: The above conjugate optionally comprises a linker between (i) and (ii), The compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is bound to the linker by an amide bond and / or the linker is bound to the N-terminus of the split intein N-fragment by an amide bond.
[0009] Another aspect of the present disclosure relates to a split intein C-fragment comprising the amino acid sequence of SEQ ID NO:7 or a variant thereof having at least 88% sequence identity to SEQ ID NO:7.
[0010] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: (i) a split intein C-fragment of the present disclosure or a split intein C-fragment comprising a sequence selected from the group consisting of SEQ ID NOs: 114-120, and (ii) Target compound A complex comprising: The above conjugate optionally comprises a linker between (i) and (ii), The compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond.
[0011] In another aspect, the present disclosure relates to a composition comprising a first conjugate and a second conjugate of the present disclosure.
[0012] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: (i) a split intein C-terminal fragment of the present disclosure or a split intein C-terminal fragment comprising a sequence selected from the group consisting of SEQ ID NOs: 114 to 120; (ii) a compound of interest, and (iii) a split intein N-terminal fragment of the present disclosure or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110 A complex comprising: the conjugate optionally comprises a linker between (i) and (ii) and / or between (ii) and (iii); the compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond; The compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the N-terminus of the split intein N-fragment by an amide bond. Concerning the complex.
[0013] Another aspect of the present disclosure relates to a conjugate comprising: (a) a first complex of the present disclosure; and (b) a split intein C-fragment comprising the amino acid sequence of SEQ ID NO:7 or a variant thereof having at least 88% sequence identity to SEQ ID NO:7, or an amino acid sequence selected from the group consisting of SEQ ID NOs:114-120, wherein the C-terminus of the split intein N-fragment is linked to the N-terminus of the split intein C-fragment by a peptide bond.
[0014] In another aspect, the present disclosure relates to a polynucleotide encoding any one of the split intein N-fragments of the present disclosure, or the split intein C-fragments of the present disclosure, or the conjugates of the present disclosure, wherein the compound of interest is a polypeptide or protein and the linker, if present, is a peptide linker.
[0015] In another aspect, the present disclosure relates to a vector comprising a polynucleotide of the present disclosure.
[0016] In another aspect, the present disclosure relates to a host cell comprising a polynucleotide or vector of the present disclosure.
[0017] In another aspect, the present disclosure relates to a composition comprising a first conjugate of the present disclosure and a second conjugate of the present disclosure.
[0018] In another aspect, the present disclosure provides a method for obtaining a conjugate between a first compound of interest and a second compound of interest, the method comprising: (i) (a) a first complex of the present disclosure comprising a first compound of interest and a split intein N-terminal fragment comprising the amino acid sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO: 1, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110; (b) a second complex of the present disclosure comprising a second compound of interest and a split intein C-terminal fragment comprising the amino acid sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity to SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120; or A complex comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof and a second compound of interest, optionally comprising a linker between said split intein C-terminal fragment and said second compound of interest, the second compound of interest is attached to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the second compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond. under conditions suitable for combining the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between the first compound of interest and the second compound of interest. The present invention relates to a method comprising the steps of:
[0019] In another aspect, the present disclosure provides a method for obtaining a conjugate between a first compound of interest and a second compound of interest, the method comprising: (i) (a) a first complex of the present disclosure comprising a first compound of interest and a split intein N-terminal fragment comprising the amino acid sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO:1, or an amino acid sequence selected from the group consisting of SEQ ID NOs:103-110; or A complex comprising a second compound of interest and an AceL-TerL split intein N-fragment or a functionally equivalent variant thereof, optionally comprising a linker between said compound of interest and the split intein N-fragment, the target compound is linked to the N-terminus of the split intein N-fragment by an amide bond, or a conjugate, wherein if said conjugate comprises a linker, said compound of interest is attached to the linker by an amide bond and / or said linker is attached to the N-terminus of the split intein N-fragment by an amide bond; (b) a second complex of the present disclosure comprising a second compound of interest and a split intein C-terminal fragment comprising the amino acid sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity to SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120. under conditions suitable for combining the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between the first compound of interest and the second compound of interest. The present invention relates to a method comprising the steps of:
[0020] In another aspect, the present disclosure provides a method for obtaining a conjugate of a target compound and a nucleophile, comprising: (i) (a) a first complex of the present disclosure, wherein the split intein N-terminal fragment comprises the amino acid sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO: 1, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110; or A complex comprising a compound of interest and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, optionally comprising a linker between said compound of interest and the split intein N-terminal fragment, the target compound is linked to the N-terminus of the split intein N-fragment by an amide bond, or a conjugate, wherein if said conjugate comprises a linker, said compound of interest is attached to the linker by an amide bond and / or said linker is attached to the N-terminus of the split intein N-fragment by an amide bond; (b) a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 9, 23 to 48, and 141 to 166; under suitable conditions to allow binding between the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) contacting the intein intermediate with an exogenous nucleophile; The present invention relates to a method comprising the steps of:
[0021] In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO:1 or a variant thereof having at least 90% sequence identity with SEQ ID NO:1, or an amino acid sequence selected from the group consisting of SEQ ID NOs:103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a variant thereof, or a sequence according to SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a variant thereof, or a sequence of SEQ ID NO: 1 or a variant thereof having at least 90% sequence identity with SEQ ID NO: 1, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising The present invention relates to a composition comprising:
[0022] In another aspect, the present disclosure provides a method for expressing a gene of interest in a cell, comprising: (i) The cell (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% thereof, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, or a sequence according to SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, or a split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% of the sequence, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising contacting the (ii) expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced; and (iii) contacting the first fusion protein with the second fusion protein such that the split intein N-terminal fragment binds to the split intein C-terminal fragment to form an intein intermediate, and such that the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest and the N-terminus of the second polypeptide of interest; The present invention relates to a method comprising the steps of:
[0023] In another aspect, the present disclosure provides a method for expressing a gene of interest, comprising: (i) The first cell is subjected to a step of, from the N-terminus to the C-terminus: a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% thereof, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. wherein said first fusion protein comprises a signal peptide; and (ii) the second cell is transfected with, from the N-terminus to the C-terminus: A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, or a sequence according to SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest with a second polynucleotide encoding a second fusion protein comprising a signal peptide; or, (i) dividing the first cell into two cells, from the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, or a split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% of the sequence, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. wherein said first fusion protein comprises a signal peptide; and (ii) the second cell is transfected with, from the N-terminus to the C-terminus: a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest with a second polynucleotide encoding a second fusion protein comprising a signal peptide; 1. expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced and secreted; and 2. contacting the first fusion protein with the second fusion protein such that the split intein N-terminal fragment binds to the split intein C-terminal fragment to form an intein intermediate, and such that the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest to the N-terminus of the second polypeptide of interest. The present invention relates to a method comprising the steps of: [Brief description of the drawings]
[0024] [Figure 1] (A)-(E) RP-HPLC analysis of the inteins used in this study. The masses corresponding to each RP-HPLC chromatogram are shown in Table 3. [Diagram 2] (A)-(D) Representative splicing gels of protein trans-splicing reactions. (A) Representative SDS-PAGE gel of protein trans-splicing reactions for Cat and AceL* at the indicated temperatures. Showing bands corresponding to MBP-IntN(N), IntC-GFP(C) and splice products (SP). (B) Representative SDS-PAGE gel of protein trans-splicing reactions for Cat and AceL* at the indicated urea concentrations. Showing bands corresponding to MBP-IntN(N), IntC-GFP(C) and splice products (SP). (C) Representative SDS-PAGE gel of protein trans-splicing reactions for Cat with the indicated -1 and -2 N-extein mutations (from the WT "FE" sequence). Showing bands corresponding to MBP-CatN(N), CatC-GFP(C) and splice products (SP). -1A and -1P mutations show C-terminal truncations and are indicated on the gel (GFP). (D) Representative SDS-PAGE gel of protein trans-splicing reactions for Cat with the indicated +2 and +3 C-extein mutations (from WT “EF”), showing bands corresponding to MBP-CatN (N), CatC-GFP (C) and the splice product (SP). [Diagram 3] (A)-(B) Reaction progress curves. (A) and (B) show the reaction progress curves for the splicing reactions performed in this study. The best-fit line for each reaction is shown. [Figure 4](A)-(D) Expression of atypical split inteins. Lanes correspond to (W) whole cell lysate, (P) inclusion body pellet, (S) soluble fraction of lysate, (FT) flow-through of soluble lysate batch bound to Ni-NTA affinity beads, (E) 3 CV elution with 250 mM imidazole. (A) Purification of SUMO-GOSC, SUMO-AceL*C, and SUMO-CatC from E. coli expression (18 °C, 16 h). (B) Purification of SUMO-GOSC, SUMO-AceL*C-Sumo, and SUMO-CatC from E. coli expression (37 °C, 3 h). (C) Purification of SUMO-GOSN, SUMO-AceL*N, and SUMO-CatN from E. coli expression (37 °C, 3 h). (D) Purification of GOSC-GFP, AceL*C-GFP, and CatC-GFP from E. coli expression (18°C, 16 h). [Diagram 5] (A)-(D) Characterization of the consensus atypical (Cat) split intein. (A) Pairwise sequence alignment of Cat and AceL* highlighting identical (black) and similar (grey) residues. (B) Reaction progress curve for Cat splicing at 30°C. (C) Splicing rates for Cat and AceL* as a function of temperature (n=3, error=SEM). AceL* is inactive at 50°C. (D) Splicing rates for Cat and AceL* as a function of added urea (n=3, error=SEM). AceL* is inactive in the presence of 2M and 4M urea (NA). [Figure 6] (A)-(D) Structural effects of Cat fragment association. (A) 1H-15N HSQC spectra of 15N-labeled CatN without unlabeled CatC (black) and in complex with unlabeled CatC (gray). (B) 1H-15N HSQC spectra of 15N-labeled CatC without unlabeled CatN (black) and in complex with unlabeled CatN (gray). (C) Far-UV circular dichroism spectra of CatN (black), CatC (dark gray), and the CatN+CatC complex (light gray). (D) Size-exclusion chromatograms of CatN (black), CatC (dark gray), and the CatN+CatC complex (light gray). [Figure 7] (A)-(D) Disordered to ordered transition of CatN. (A) (15N-1H) heteronuclear NOE of CatN in the presence (left) and absence (right) of CatC. (B) Spin-spin relaxation rate of CatN in the presence (left) and absence (right) of CatC. (C) Perturbation of Cα and Cβ chemical shifts of CatN in the presence (left) and absence (right) of CatC. Δδ(Cα,Cβ)=(δCβ-δCα)Observed-(δCβ-δCα)Random Coil. [Figure 8] (A)-(C) Solution NMR structure of Cat. (A) Backbone conformations of the 20 lowest energy conformers obtained from the structure calculation of the CatN (dark)-CatC (light) split intein complex. The CatC solubility tag is shown in transparent grey. The structure is shown rotated 180° (top and bottom views). (B) Animated representation of the lowest energy conformer. The structure is shown rotated 180° (top and bottom views). (C) Close-up of the Cat active site showing Ala1, Ser75, His78, and His133 as sticks. Distances between the carbonyl oxygen of Ala1 and the amide and hydroxyl protons of Ser75 are shown. [Figure 9] (A)-(C) Structure of the Cat complex. (A) Average per residual Root Mean Square Deviation (RMSD) from the average structure of the 20 lowest energy conformers of the CatN-CatC complex obtained by NMR structure calculation. (B) Average per residual RMSD plotted against the number of residues for the CatN (grey)-CatC (black) complex. The extein region is shown in grey and the solubility tag used with CatC is shown as a dashed line. (C) Sequence logos of the block B loop (left), block F loop (center) and C-terminal block G (right) generated from an alignment of TerL intein homologs (Table 1). [Figure 10](A)-(C) Localization of disorder in Cat fragments. (A) RP-HPLC chromatograms obtained from limited proteolysis of CatN (left), CatC (middle) and the 1:1 CatN+CatC complex (right) with samples quenched after the indicated times. (B) Sequence of Cat with disordered regions of CatC highlighted in dark grey and conserved centers highlighted in light grey. (C) Model of Cat disorder mapped onto the NMR structure with the N-intein highlighted in light grey, disordered regions of CatC highlighted in dark grey and conserved centers highlighted in medium grey. A close-up of the active site is shown with splicing residues as sticks. [Figure 11] (A)-(B) RP-HPLC analysis of limited proteolysis of Cat fragments. (A) RP-HPLC results from CatN (left) and CatC (right) proteolysis experiments (t=30 min) with numbered samples corresponding to the ESI-MS data in Table 8. (B) Primary sequences of the CatN and CatC inteins used in the limited proteolysis experiments (detected proteolytic fragments are shown below in brackets). Numbers in each bracket correspond to the RP-HPLC peaks in panel A. [Figure 12] (A)-(D) Hydrophobic residues drive Cat association. (A) Surface rendering of CatN with hydrophobic residues colored in grayscale based on the standardized consensus hydrophobicity scale. CatC is animated. (B) Surface rendering of CatC showing hydrophobic residues in grayscale. CatN is animated. (C) Equilibrium fluorescence anisotropy measurements of Fl-CatN (500 pM) in the presence of SUMO-CatC (concentrations shown) in low-salt (100 mM NaCl black) and high-salt (500 mM NaCl grey dashed) buffers. (D) Concentration dependence of the resulting Fl-CatN + SUMO-CatC association rates in low-salt (100 mM NaCl black) and high-salt (500 mM NaCl grey dashed) buffers. [Figure 13](A)-(C) Cat electrostatic surfaces. (A) Electrostatic surface potential of CatN (electronegative regions are colored in smooth grayscale, electropositive regions are colored in patterned grayscale, and neutral regions are colored in white) is animated. (B) Electrostatic surface potential of CatC (electronegative regions are colored in smooth grayscale, electropositive regions are colored in patterned grayscale, and neutral regions are colored in white) is animated. CatN. (C) Representative data and fits from kinetic binding experiments. Top: Single exponential (left) and double exponential (right) models of nonlinear least-squares fitting of stopped-flow anisotropy measurements of Fl-CatN when mixed with SUMO-CatC. Bottom: Residual values obtained between experimental and predicted values are plotted for single exponential fits (left) and double exponential fits (right). [Figure 14] (A)-(E) Extein dependency of Cat. (A) Schematic of the assay used to examine the effect of local extein sequences on Cat splicing. N-extein maltose binding protein (MBP) is fused to CatN, and C-extein green fluorescent protein (GFP) is fused to CatC. The native extein sequences (Phe-2, Glu-1, Cys+1, Glu+2, Phe+3) are shown in these fusion proteins. (B) Splicing rate of Cat in the presence of non-native C-extein residues (n=3, error=SEM). Each value shown corresponds to a single point mutation in the C-extein from the wild-type (WT) sequence. (C) Splicing rate of Cat in the presence of non-native N-extein residues (n=3, error=SEM). Each value shown corresponds to a single point mutation in the N-extein from the wild-type (WT) sequence. (D) Close-up of the Cat active site showing Cys+1, Glu+2, Asp115, Asn123, His133, and Ala134 as sticks. (E) Close-up of the Cat active site showing Glu-1, Ala1, Ser75, and His78 as sticks. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] Detailed Description of the Invention The present disclosure provides novel atypical split inteins and their uses in biochemical engineering.
[0026] Split intein N-terminal fragment In a first aspect, the present disclosure relates to a split intein N-fragment comprising the amino acid sequence of SEQ ID NO:1 or a variant thereof having at least 90% sequence identity to SEQ ID NO:1.
[0027] As used herein, the term "intein" refers to a naturally occurring or artificially constructed polypeptide sequence that can catalyze a protein splicing reaction that excises the intein sequence from a precursor protein and joins adjacent sequences (N-extein and C-extein) with a peptide bond. Inteins are generally 150-550 amino acids in size and may also contain a homing endonuclease domain. A list of known inteins is published at https: / / inteins.biocenter.helsinki.fi / .
[0028] The terms "polypeptide," "peptide" or "protein" are used interchangeably herein to refer to amino acid polymers of any length.
[0029] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Additionally, the term "amino acid" includes both D- and L-amino acids (stereoisomers).
[0030] The term "natural amino acid" or "naturally occurring amino acid" comprises the 20 naturally occurring amino acids, which often undergo post-translational modifications in vivo, such as hydroxyproline, phosphoserine, and phosphothreonine; as well as other unusual amino acids, including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, norvaline, norleucine, and ornithine.
[0031] As used herein, the term "unnatural amino acid" or "synthetic amino acid" refers to a derivative thereof that is substituted with a carboxylic acid or amine group and is structurally related to a natural amino acid. Illustrative non-limiting examples of modified or unusual amino acids include 2-aminoadipic acid, 3-aminoadipic acid, β-alanine, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4-diaminobutyric acid, desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, alloisoleucine, N-methylglycine, N-methylisoleucine, 6-N-methyl-lysine, N-methylvaline, norvaline, norleucine, ornithine, etc. This group also includes the D-isomers of the "natural amino acids."
[0032] The term "split intein," as used herein, refers to any intein in which the N-terminal and C-terminal amino acid sequences are not directly linked by a peptide bond, such that the N-terminal and C-terminal sequences are separate fragments that can non-covalently reassociate or reconstitute into an intein that is functional for a trans-splicing reaction.
[0033] As used herein, the term "split intein N-terminal fragment" or "N-terminal split intein" or "N-terminal intein fragment" or "N-terminal intein sequence" (abbreviated as "Int N") refers to any intein sequence that is functional for a trans-splicing reaction, i.e., that can associate with a functional split intein C-terminal fragment to form an intact intein that can excised itself from a host protein and catalyze the ligation of an extein or an adjacent sequence by a peptide bond, or that comprises an N-terminal amino acid sequence that, when associated with a split intein C-terminal fragment, catalyzes "N-terminal cleavage", i.e., nucleophilic attack of the peptide bond between the extein and the N-terminus of the split intein N-terminal fragment, resulting in the rupture of said peptide bond.
[0034] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, it should be noted that reference to "a split intein" includes a plurality of such split inteins, reference to "the polypeptide" includes one or more polypeptides and equivalents thereof known to those skilled in the art, and so forth.
[0035] In certain embodiments, the split intein N-fragment comprises the amino acid sequence of SEQ ID NO: 1. The split intein N-fragment can comprise additional amino acid residues linked to the N-terminus and / or C-terminus of the sequence of SEQ ID NO: 1. In certain embodiments, the split intein N-fragment comprises fewer than 10, fewer than 9, fewer than 8, fewer than 7, fewer than 6, fewer than 5, fewer than 4, fewer than 3, fewer than 2, or fewer than 1 additional amino acid residues linked to the N-terminus and / or C-terminus of the sequence of SEQ ID NO: 1. In another embodiment, the split intein N-fragment consists of the amino acid sequence of SEQ ID NO: 1.
[0036] In certain embodiments, the split intein N-fragment comprises or consists of a variant of the amino acid sequence of SEQ ID NO:1 that has at least 90% sequence identity to SEQ ID NO:1.
[0037] The term "variant" as used herein refers to a polypeptide molecule that is substantially similar to a particular polypeptide sequence. The variant may be similar in structure and biological activity to the polypeptide from which it is derived. Thus, a variant may refer to a mutant of a polypeptide sequence. The term "mutant" refers to a polypeptide molecule whose sequence has one or more amino acid additions, deletions, substitutions, or other chemical modifications compared to the polypeptide molecule from which it is derived. A mutant may retain substantially the same properties as the polypeptide molecule from which it is derived, or may lack the biological activity of the claimed sequence.
[0038] A variant of the split intein N-fragment of SEQ ID NO:1 has at least 90% sequence identity to SEQ ID NO: 1. In certain embodiments, a variant of the split intein N-fragment of SEQ ID NO:1 has at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:1.
[0039] In certain embodiments of this aspect of the disclosure, variants of the split intein N-fragment of SEQ ID NO:1 have a length of 14 to 60 amino acids, e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60 amino acids.
[0040] The terms "identity", "identical", "percent identity" or "sequence identity" in reference to two or more amino acid or nucleotide sequences refer to two or more sequences or subsequences that are the same or have a certain percentage of amino acid residues that are the same when compared and aligned for maximum correspondence (introducing gaps, if necessary), without considering conservative amino acid substitutions as part of the sequence identity. Percent identity can be assessed using sequence comparison software or algorithms, or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignment of amino acid sequences. One such non-limiting example of a sequence alignment algorithm is described in Karlin et al., 1990, Proc. Natl. Acad. Sci., 87:2264-8, modified in Karlin et al., 1993, Proc. Natl. Acad. Sci., 90:5873-7, and incorporated into the NBLAST and XBLAST programs (Altschul et al., 1991, Nucleic Acids Res., 25:3389-402). In certain embodiments, Gapped BLAST can be used as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-402. BLAST-2, WU-BLAST-2 (Altschul et al., 1996, Methods in Enzymology, 266:460-80), ALIGN, ALIGN-2 (Genentech, South San Francisco, Calif.) or Megalign (DNASTAR) are further publicly available software programs that can be used to align sequences. In certain alternative embodiments, the GAP program of the GCG software package, incorporating the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-53 (1970)), can be used to determine the percent identity between two amino acid sequences (e.g., using the Blossum 62 matrix). or using a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5). Alternatively, in certain embodiments, percent identity between amino acid sequences is determined using the algorithm of Myers and Miller (CABIOS, 4:1 1 -7 (1989)). For example, percent identity can be determined using the ALIGN program (version 2.0) using PAM120 with a residue table, a gap length penalty of 12, and a gap penalty of 4. Appropriate parameters for maximal alignment with a particular alignment software can be determined by one of skill in the art. In certain embodiments, the default parameters of the alignment software are used. In certain embodiments, the identity percentage "X" of a first amino acid sequence to a second amino acid sequence is calculated as 100 x (Y / Z), where Y is the number of amino acid residues scored as identical matches in the alignment (by eye or by a specific sequence alignment program) of the first and second sequences, and Z is the total number of residues in the second sequence. If the second sequence is longer than the first sequence, a global alignment is used that takes into account the entirety of both sequences, and therefore all characters and nulls in each sequence must be aligned. In this case, the same formula as above can be used, but the Z value is the length of the region where the first and second sequences overlap, which has substantially the same length as the first sequence.
[0041] As a non-limiting example, whether any particular polypeptide has a particular percentage of sequence identity to a reference sequence (e.g., at least 80% identical, at least 85% identical, at least 90% identical, and in some embodiments at least 95%, 96%, 97%, 98%, or 99% identical) can, in certain embodiments, be determined using the Bestfit program (Wisconsin Sequence Analysis Package for Unix, Version 8, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wl 5371 1). Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-9 (1981) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence in accordance with the present disclosure, parameters are set such that the percentage of identity is calculated over the entire length of the reference amino acid sequence and allow gaps in homology of up to 5% of the total number of nucleotides in the reference sequence.
[0042] In certain embodiments, a variant of the split intein N-fragment of SEQ ID NO:1 has at least 90% sequence identity with SEQ ID NO:1 over the entire length of the sequence.
[0043] In certain embodiments, the variant of the split N-intein fragment of SEQ ID NO: 1 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-6, and 125-127.
[0044] In another embodiment, the variant of the split N-intein fragment of SEQ ID NO:1 is a functionally equivalent variant of SEQ ID NO:1.
[0045] The term "functionally equivalent variants", as used herein, is understood to mean all proteins derived from a sequence by modification, insertion and / or deletion of one or more amino acids, if their function is substantially maintained, in particular in the case of functionally equivalent variants of split intein N-fragments, which maintain their activity.
[0046] In certain embodiments, a functionally equivalent variant of the split intein N-fragment of SEQ ID NO:1 maintains or improves the activity of the split intein N-fragment of SEQ ID NO:1.
[0047] The term "activity" as used herein with respect to a split intein N-terminal fragment refers to the ability of the split intein N-terminal fragment to bind to a split intein C-terminal fragment and catalyze "N-terminal cleavage", i.e., nucleophilic attack of the peptide bond between the extein and the N-terminus of the split intein N-terminal fragment, resulting in the breakage of said peptide bond. The activity of a split intein N-terminal fragment can also be referred to as "trans-splicing activity", which is understood as the ability of said split intein N-terminal fragment to bind to a functional split intein C-terminal fragment, excise the complete intein from the host protein, and catalyze the ligation of the extein or adjacent sequence by a peptide bond. This activity depends on the reaction conditions, including temperature, pH, and the presence of chaotropic agents. The conventional unit is t 1 / 2 , which represents the time for half of the catalyzed reaction to be completed. Furthermore, intein activity is also assessed by the rate constant (k) of the catalyzed reaction, i.e., how many reactions occur per second.
[0048] Suitable assays for determining whether a polypeptide is a functionally equivalent variant of a given split N-intein with respect to its trans-splicing activity include splicing assays such as those described in the present application or in the method disclosed in Shah NH et al (Shah NH et al., 2012, J Chem Soc, vol 134, 11338), insofar as in these assays a split intein N-terminal fragment is combined with a functional split intein C-terminal fragment, i.e. a split intein C-terminal fragment capable of catalyzing "C-terminal cleavage". The above assays allow the determination and characterization of a trans-splicing reaction in which functional N- and C-intein fragments bind to each other and then carry out a reaction in which they excise themselves and generate a new peptide bond between the N- and C-extein. Other assays have been developed that rely on the use of functional N-inteins and C-intein mutants that prevent trans-splicing, so that the reaction is stopped after the N-extein is excised from the N-intein. Such assays (Vila-Perello et al. J Am Cem Soc. 2013, 135(1): 286-292) allow characterization of the ability of the N-intein to carry out the N-terminal cleavage reaction. In addition, other assays exist to measure the affinity between N-terminal inteins and C-terminal inteins (Shah et al. Angew Chem Int Ed Engl. 2011, 50(29): 6511-5).
[0049] According to the present disclosure, the activity of a split N-intein of the present disclosure is substantially maintained if a functional equivalent has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% of its activity. Furthermore, the activity of a split N-intein of the disclosure is substantially improved if a functionally equivalent variant has at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 1000% or more of its activity.
[0050] As mentioned above, the activity of the split N-inteins of the present disclosure depends on several reaction parameters, including temperature, chaotropic environment, and pH. Thus, in one embodiment, a functionally equivalent variant of a split intein N-fragment of the present disclosure maintains or improves its activity at a temperature of at least 0°C, at least 5°C, at least 10°C, at least 15°C, at least 20°C, at least 25°C, at least 30°C, at least 35°C, at least 37°C, at least 40°C, at least 45°C, at least 50°C, at least 55°C, at least 60°C, at least 65°C, at least 70°C or higher, and in a particular embodiment, at a temperature of 50°C. Similarly, in another embodiment, a functionally equivalent variant of a split N-intein of the disclosure has a pH of at least 2.0, or at least 2.5, or at least 3.0, or at least 3.5, or at least 4.0, or at least 4.5, or at least 5.0, or at least 5.5, or at least 6.0, or at least 6.5, or at least 7.0, or at least 7.2, or at least 7.5, or at least pH 8.0, or at least pH 8.5, or at least pH 9.0, or at least pH 9.5, or at least pH 10.0, or at least pH 10.5, or at least pH 11.0, or at least pH 11.5, or at least pH 12.0, or at least pH 12.5, or at least pH 13.0, or at least pH 13.5, or at least pH 14, and in certain embodiments at pH 7.2. In another embodiment, a functionally equivalent variant of a split N-intein of the disclosure maintains or improves its activity at 1 M urea, or at least 1.5 M urea, or at least 2 M urea, or at least 3 M urea, or at least 3.5 M urea, or at least 4 M urea, or at least 4.5 M urea, or at least 5 M urea, and in certain embodiments at 2 M urea or 4 M urea.In certain embodiments, functionally equivalent variants of the split N-inteins of the disclosure maintain or improve their activity at urea 2 M or urea 4 M. In certain embodiments, functionally equivalent variants of the split N-inteins of the disclosure maintain or improve their activity at a temperature of 50° C., at pH 7.2, and at urea 2 M or urea 4 M. All possible combinations of temperature, urea concentration, other denaturants, and pH are also contemplated by the present invention.
[0051] In certain embodiments, functionally equivalent variants of the split intein N-fragments of the disclosure that maintain or improve their activity have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:1.
[0052] In another embodiment, a functionally equivalent variant of the split intein N-fragment of SEQ ID NO:1 comprises or consists of the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:125.
[0053] Complexes Comprising Split Intein N-Terminal Fragments In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: (i) target compound, (ii) a split intein N-terminal fragment of the present disclosure, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. A complex comprising: The above conjugate optionally comprises a linker between (i) and (ii), The compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond, or When the conjugate comprises a linker, the compound of interest is bound to the linker by an amide bond and / or the linker is bound to the N-terminus of the split intein N-fragment by an amide bond.
[0054] As used herein, the term "compound of interest" includes any synthetic or naturally occurring molecule, including proteins or peptides, single- or double-stranded oligonucleotides, small molecule drugs, or cytotoxic molecules. Thus, the term encompasses compounds traditionally considered to be drugs, vaccines, and biologics, including molecules such as proteins, peptides, and the like. Examples of therapeutic agents are described in well-known texts, such as the Merck Index (14th Edition), the Physician's Desk Reference (64th Edition), and The Pharmacological Basis of Therapeutics (1st Edition), and include, but are not limited to, drugs; substances used to treat, prevent, diagnose, cure, or mitigate disease or illness; substances that affect the structure or function of the body; or prodrugs that become biologically active or more active after being placed in a physiological environment. In addition, "compound of interest" can include any non-protein molecule that has a carboxyl group that can be attached to the amino terminus of an N-intein.
[0055] Optionally, the compound of interest and the split intein N-terminal fragment may be linked via a linker, and thus the linker is placed between the compound of interest and the N-intein. The nature of the linker varies depending on the nature of the compound of interest. In certain embodiments, the linker is a peptide. In certain embodiments, the linker is a peptide having a length of 1, 2, 3, 4, 5, 10, 20, 50, 100 or more amino acid residues; specifically, it may be 1 to 3 amino acid residues. When the compound of interest is a peptide or protein, the N-terminus of the linker is linked to the C-terminus of the compound of interest, and the C-terminus of the linker is linked to the N-terminus of the N-intein via a peptide bond.
[0056] In certain embodiments, the linker is a non-peptide linker. The non-peptide linker can be, for example, an alkyl linker, such as -HN-(CH2)s-CO-, where s=2 to 20. These alkyl linkers can be further substituted with any non-sterically hindering group, such as lower alkyl (e.g., Ci-Ce), halogen (e.g., Cl, Br), CN, NH2, or phenyl.
[0057] Another type of non-peptide linker is a polyethylene glycol group, e.g., -HN-(CH2)2-(0-CH2-CH2)n-0-CH2-CO, where n is such that the total molecular weight of the linker is in the range of approximately 101-5000, and in certain embodiments, 101-500.
[0058] In another embodiment, the non-peptide linker comprises a base nucleotide, a polyether, a polyamine, a polyamide, a carbohydrate, a lipid, a polyhydrocarbon, or other polymeric compound.
[0059] In certain embodiments, the conjugate does not include a linker between the compound of interest and the split intein N-fragment, in which the compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond.
[0060] In certain embodiments, the complex comprises a linker between the compound of interest and the split intein N-fragment. In this embodiment, the compound of interest may be attached to the linker by any suitable means depending on the chemical nature of the compound of interest and the linker. In this embodiment, the linker is attached to the N-terminus of the split intein N-fragment by an amide bond. In another embodiment, the compound of interest is attached to the linker by an amide bond, in which case the linker may be found at the N-terminus of the split intein N-fragment by any suitable means. In another embodiment, the compound of interest is attached to the linker by an amide bond, and the linker is attached to the N-terminus of the split intein N-fragment by an amide bond.
[0061] In another embodiment, the compound of interest is a protein having a C-terminal amino acid residue of an extein that can be spliced by an intein comprising the N-intein of SEQ ID NO: 1. In another embodiment, the compound of interest is a protein having the sequence Glu-Phe-Glu at its C-terminus. In another embodiment, the compound of interest is a protein having the sequence Phe-Glu at its C-terminus. In another embodiment, the compound of interest is a protein having the residue Glu at its C-terminus.
[0062] In another embodiment, when the compound of interest is not a protein, the N-intein comprises or consists of a polypeptide of SEQ ID NO: 4-6, 125-127, or 168-170. In another embodiment, when the compound of interest is not a protein, the compound of interest and the N-intein are linked via a linker, in which case the linker is a peptide having the C-terminal amino acid residues of an extein that can be spliced by an intein comprising a split intein N-terminal fragment of the sequence of SEQ ID NO: 1, and in a particular embodiment, the linker is a peptide having the sequence Glu-Phe-Glu, Phe-Glu, or Glu at its C-terminus.
[0063] In another embodiment, the compound of interest is a protein that does not have a C-terminal amino acid residue of an extein that can be spliced by an intein comprising a split intein N-terminal fragment of SEQ ID NO: 1, in which case (i) the N-intein comprises or consists of a polypeptide of a sequence of SEQ ID NO: 4-6, 125-127, or 168-170, or (ii) the compound of interest and the N-intein are linked via a linker, in which case the linker is a peptide that has a C-terminal amino acid residue of an extein that can be spliced by an intein comprising a split intein N-terminal fragment of SEQ ID NO: 1, in certain embodiments the linker is a peptide having the sequence Glu-Phe-Glu, Phe-Glu, or Glu at its C-terminus.
[0064] The phrase "peptide bond" refers to a covalent chemical bond -CO-NH- that forms between two molecules when the carboxy portion of one molecule (called the carboxy component) reacts with the amino portion of the other molecule (called the amino component), causing the release of the molecule. For example, the L-amino acids that make up proteins can form peptide bonds when they link together with the release of one molecule of water. Thus, proteins and peptides can be viewed as chains of amino acid residues held together by peptide bonds. A peptide bond is an "amide bond" or "amide linkage."
[0065] In certain embodiments, the compound of interest is a protein or polypeptide.
[0066] In another embodiment, the compound of interest is a protein greater than 25 KDa, greater than 50 KDa or greater than 100 KDa.
[0067] In certain embodiments, the protein is Cas9 or a fragment of Cas9. The term "Cas9" or "CRISPR-associated endonuclease Cas9" as used herein refers to a protein that is a characteristic protein of the type II CRISPR-Cas system and is a large monomeric DNA nuclease that is guided to DNA target sequences adjacent to a PAM (protospacer adjacent motif) sequence motif by a complex of two non-coding RNAs: CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA). Cas9 protein contains two nuclease domains that are homologous to RuvC and HNH nuclease. The HNH nuclease domain cleaves the complementary DNA strand, and the RuvC-like domain cleaves the non-complementary strand, resulting in the introduction of a blunt break in the target DNA. Heterologous expression of Cas9 together with sgRNA can introduce site-specific double-strand breaks (DSBs) in genomic DNA of living cells of various organisms. Cas9 may be of any origin, including, for example, Streptococcus thermophilus, Streptococcus pyogenes, Staphylococcus aeureus, Francisella tularensis, Actinomyces naeslundii, Neiserria meningitides, Listeria innocua, among others.In certain embodiments, the term "Cas9" refers to any of the polypeptides listed in UniProtKB / Swiss-Prot accession numbers G3ECR1 (entry version 31 of April 10, 2019, sequence version 2 of June 13, 2012), Q99ZW2 (entry version 112 of July 31, 2019, sequence version 1 of June 1, 2001), J7RUA5 (entry version 33 of May 8, 2019, sequence version 1 of October 31, 2012), A0Q5Y3 (entry version 62 of January 16, 2019, sequence version 1 of January 9, 2007), and / or A0Q5Y4 (entry version 62 of January 16, 2019, sequence version 1 of January 9, 2007). This refers to any one of the proteins defined by entry version 1 of 2019-05-08, sequence version 1 of 2012-10-03, J3F2B0 (entry version 33 of 2019-05-08, sequence version 1 of 2012-11-14), Q03JI6 (entry version 70 of 2019-05-08, sequence version 1 of 2006-11-14), C9X1G5 (entry version 47 of 2019-07-31, sequence version 1 of 2009-11-24), or Q927P4 (entry version 94 of 2019-05-08, sequence version 1 of 2001-12-01).
[0068] In certain embodiments, the target compound of the conjugate is a polypeptide or a protein, and when the conjugate comprises a linker, the linker is a peptide linker. In this embodiment, the conjugate is a fusion protein.
[0069] The term "fusion protein" is well known in the art and refers to an artificially designed single polypeptide chain comprising two or more sequences derived from different natural and / or artificial sources. Fusion proteins, by definition, are not found in nature as such.
[0070] The term "single polypeptide chain" as used herein means that the polypeptide components of the fusion protein can be conjugated end-to-end or can include one or more optional peptide or polypeptide "linkers" or "spacers" interposed between them that are covalently linked.
[0071] In another embodiment, the polypeptide of interest is an antibody or a fragment of an antibody.
[0072] As used herein, the term "antibody" refers to a monomeric or multimeric protein comprising at least one polypeptide comprising all or part of a light or heavy chain having binding capacity to a determined antigen or epitope within an antigen.
[0073] The term antibody also includes any type of known antibody, such as, for example, polyclonal antibodies, monoclonal antibodies, and genetically engineered antibodies, e.g., chimeric antibodies, humanized antibodies, primatized antibodies, human antibodies, camelid antibodies, and bispecific antibodies (including diabodies), multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
[0074] The term "antibody fragment" includes antibody fragments such as Fab, F(ab')2, Fab', single chain Fv fragments (scFv), diabodies and nanobodies.
[0075] An illustrative, non-limiting example of an antibody is an antibody against the DEC-205 receptor. The term "DEC-205 receptor", or "lymphocyte antigen 75", or "C-type lectin domain family 13 member B", as used herein, refers to a protein found primarily on dendritic cells that acts as an endocytic receptor to direct captured antigens from the extracellular space to specialized antigen processing compartments. In certain embodiments, DEC-205 is a human protein defined by UniProtKB / Swiss-Prot Accession No. O60449 (Entry version 170 of July 31, 2019, sequence version 3 of January 11, 2011). In certain embodiments, the anti-DEC205 antibody is a monoclonal antibody. The anti-DEC-205 antibody may be of any origin, such as, for example, mouse, rabbit, human, or may be a humanized antibody. In certain embodiments, the compound of interest is a chain of the anti-DEC-205 antibody, in certain embodiments, the heavy chain. In another embodiment, the compound of interest is the heavy chain of the murine αDEC-205 monoclonal antibody as described by Stevens et al., JACS 2016, 138: 2162-5.
[0076] In another embodiment, the compound of interest is a fragment of a protein, in particular embodiments, a fragment of a protein greater than 25 KDa, greater than 50 KDa, or greater than 100 KDa.
[0077] In another embodiment, the compound of interest is an N-terminal fragment of a protein, in certain embodiments, a fragment of a protein that is greater than 25KDa, greater than 50KDa, or greater than 100KDa. The term "N-terminal fragment of a protein" as used herein refers to a fragment of various lengths that includes the N-terminus of a protein. In certain embodiments, the N-terminal fragment is a fragment that comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the length of the full-length protein.
[0078] In certain embodiments, the complex comprises a split intein N-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 111, 112 and 113.
[0079] In certain embodiments, the sequences of SEQ ID NO:112 and 113 have a higher temperature stability than the sequence of SEQ ID NO:1.
[0080] In certain embodiments, the complex comprises a split intein N-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-68 or variants thereof. In certain embodiments, the variant is a functionally equivalent variant.
[0081] The terms "variant" and "functionally equivalent variant" have been defined previously. In certain embodiments, functionally equivalent variants of the split intein N-fragments of SEQ ID NOs: 49-68 have at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to the sequences from which they are derived.
[0082] In certain embodiments, functionally equivalent variants of the split intein N-fragment of SEQ ID NO: 49-68 maintain or improve the activity of the sequence from which they are derived. The term "activity" as well as methods for measuring this activity have been previously defined for functionally equivalent variants of the split intein N-fragment of SEQ ID NO: 1. The embodiments relating to the activity of variants of the split intein N-fragment of SEQ ID NO: 1 also apply directly to the activity of variants of the split intein N-fragment of SEQ ID NO: 49-68.
[0083] Split intein C-terminal fragment In another aspect, the disclosure relates to a split intein C-fragment comprising the amino acid sequence of SEQ ID NO:7 or a variant thereof having at least 88% sequence identity to SEQ ID NO:7.
[0084] As used interchangeably herein, the terms "split intein C-terminal fragment," "C-terminal split intein," "C-terminal intein fragment," and "C-terminal intein sequence" ("Intein C-terminal fragment"). C ") refers to any intein sequence that is functional with respect to a trans-splicing reaction, i.e., that can associate with a functional split intein N-fragment to form an intact intein that can excise itself from a host protein and catalyze the ligation of an extein or an adjacent sequence by a peptide bond, or that comprises a C-terminal amino acid sequence that, when associated with a split N-intein, catalyzes a "C-terminal cleavage", i.e., a nucleophilic attack of the peptide bond between the extein and the C-terminus of the split intein C-fragment, resulting in the rupture of said peptide bond. Thus, Int C It also comprises a sequence that is removed by splicing when trans-splicing occurs. C can comprise a sequence as a modification of the C-terminal portion of a naturally occurring intein sequence. For example, it can comprise additional amino acid residues and / or mutated residues (the inclusion of such additional and / or mutated residues can be used to modify the Intein sequence). C In certain embodiments, the inclusion of additional and / or mutated residues is C Improve or enhance the trans-splicing activity of.
[0085] In certain embodiments, the split intein C-fragment comprises the amino acid sequence of SEQ ID NO: 7. The split intein C-fragment can comprise additional amino acid residues linked to the N-terminus and / or C-terminus of the sequence of SEQ ID NO: 7. In certain embodiments, the split intein C-fragment comprises fewer than 10, fewer than 9, fewer than 8, fewer than 7, fewer than 6, fewer than 5, fewer than 4, fewer than 3, fewer than 2, or fewer than 1 additional amino acid residues linked to the N-terminus and / or C-terminus of the sequence of SEQ ID NO: 7. In another embodiment, the split intein N-fragment consists of the amino acid sequence of SEQ ID NO: 7.
[0086] In certain embodiments, the split intein C-fragment comprises or consists of a variant of the amino acid sequence of SEQ ID NO:7 that has at least 88% sequence identity to SEQ ID NO:7.
[0087] The terms "amino acid" and "variant" have already been described with respect to N-inteins and apply in this case as well.
[0088] A variant of a split intein C-fragment of SEQ ID NO:7 has at least 88% sequence identity to SEQ ID NO:7. In certain embodiments, a variant of a split intein C-fragment of SEQ ID NO:7 has at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to SEQ ID NO:7.
[0089] In certain embodiments, variants of the split intein C-fragment of SEQ ID NO: 7 have a length of 50 to 160 amino acids, and in certain embodiments, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155 or 160 amino acids.
[0090] In certain embodiments, a variant of the split intein C-fragment of SEQ ID NO:7 has at least 88% sequence identity with SEQ ID NO:7 over the entire length of the sequence.
[0091] In a particular embodiment, the split intein C-fragment variant of sequence SEQ ID NO: 7 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 848 and 128-166.
[0092] In another embodiment, the variant of the split C-intein of SEQ ID NO:7 is a functionally equivalent variant of SEQ ID NO:7.
[0093] The term "functionally equivalent variant" has been previously defined for split intein C-terminal fragments. In the case of a functionally equivalent variant of the split intein C-terminal fragment of SEQ ID NO: 7, the activity of the split intein C-terminal fragment refers to its ability to bind to the split intein N-terminal fragment and catalyze "C-terminal cleavage", i.e., the nucleophilic attack of the peptide bond between the extein and the C-terminus of the split intein C-terminal fragment, resulting in the breakage of said peptide bond. The activity of the split intein C-terminal fragment may also be referred to as "trans-splicing activity", which is understood as the ability of said split intein C-terminal fragment to bind to a functional split intein N-terminal fragment, excise the complete intein from the host protein, and catalyze the linkage of the extein or adjacent sequence by a peptide bond. Suitable assays for determining whether a polypeptide is a functionally equivalent variant of a given split C-intein with respect to its trans-splicing activity include splicing assays such as those described in the present application or in the method disclosed in Shah NH et al (Shah NH et al., 2012, J Chem Soc, vol 134, 11338), as long as in these assays a split intein C-fragment is combined with a functional split intein N-fragment, i.e. a split intein N-fragment capable of catalyzing N-terminal cleavage. Other more detailed assays have also been described that allow the characterization of each step of protein splicing, in particular the final step involving the cleavage of the peptide bond between the C-intein and the C-extein, referred to herein as "C-terminal cleavage" (Shah et al. JACS 2013).
[0094] According to the present disclosure, the activity of a C-intein is substantially maintained if its functional equivalent has at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% of the activity of the intein of the claimed sequence. Furthermore, the activity of a C-intein is substantially improved if a functionally equivalent variant has at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 1000% or more of the activity of a C-intein of the disclosure.
[0095] As mentioned above, the activity of the split intein C-fragment of the present disclosure depends on several reaction parameters, including temperature, chaotropic environment, and pH. Thus, in one embodiment, a functionally equivalent variant of a split intein C-fragment of the present disclosure maintains or improves its activity at a temperature of at least 0°C, at least 5°C, at least 10°C, at least 15°C, at least 20°C, at least 25°C, at least 30°C, at least 35°C, at least 37°C, at least 40°C, at least 45°C, at least 50°C, at least 55°C, at least 60°C, at least 65°C, at least 70°C, or higher. In a particular embodiment, a functionally equivalent variant of a split intein C-fragment of the present disclosure maintains or improves its activity at a temperature of 50°C. Similarly, in another embodiment, a functionally equivalent variant of a split intein C-fragment of the disclosure has a pH of at least 0.1, or at least 0.5, or at least 1.0, or at least 1.5, or at least 2.0, or at least 2.5, or at least 3.0, or at least 3.5, or at least 4.0, or at least 4.5, or at least 5.0, or at least 5.5, or at least 6.0, or at least 6.5, or or at least pH 7.0, or at least pH 7.2, or at least pH 7.5, or at least pH 8.0, or at least pH 8.5, or at least pH 9.0, or at least pH 9.5, or at least pH 10.0, or at least pH 10.5, or at least pH 11.0, or at least pH 11.5, or at least pH 12.0, or at least pH 12.5, or at least pH 13.0, or at least pH 13.5, or at pH 14. In certain embodiments, a functionally equivalent variant of a split intein C-fragment of the disclosure maintains or improves its activity at pH 7.2.In another embodiment, a functionally equivalent variant of a split intein C-fragment of the disclosure maintains or improves its activity at 1 M urea, or at least 1.5 M urea, or at least 2 M urea, or at least 3 M urea, or at least 3.5 M urea, or at least 4 M urea, or at least 4.5 M urea, or at least 5 M urea. In certain embodiments, a functionally equivalent variant of a split C-intein of the disclosure maintains or improves its activity at 2 M urea or 5 M urea. In certain embodiments, a functionally equivalent variant of a split C-intein of the disclosure maintains or improves its activity at a temperature of 50° C., pH 7.2, and 2 M urea or 4 M urea. All possible combinations of temperature, urea concentration, and pH are contemplated by the present invention.
[0096] In certain embodiments, functionally equivalent variants of a split intein C-fragment of the disclosure that maintain or improve its activity have at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:7.
[0097] In another embodiment, the functionally equivalent variant of the split intein C-fragment comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-22 and 128-140.
[0098] Complexes Comprising Split Intein C-Terminal Fragments In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: (i) a split intein C-terminal fragment of SEQ ID NO: 7 or a split intein C-terminal fragment comprising a sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and (ii) Target compound A complex comprising: The above conjugate optionally comprises a linker between (i) and (ii), The compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond, or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond.
[0099] The terms "target compound" and "linker" are defined above with respect to the first conjugate of the present disclosure. All target compound and linker embodiments of the first conjugate of the present disclosure apply directly to the second conjugate of the present disclosure.
[0100] In certain embodiments, the conjugate does not include a linker between the compound of interest and the split intein C-fragment, in which the compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond.
[0101] In certain embodiments, the conjugate comprises a linker between the compound of interest and the split intein C-fragment. In this embodiment, the compound of interest may be attached to the linker by any suitable means depending on the chemical nature of the compound of interest and the linker. In this embodiment, the linker is attached to the C-terminus of the split intein C-fragment by an amide bond. In another embodiment, the compound of interest is attached to the linker by an amide bond, in which case the linker may be attached to the C-terminus of the split intein C-fragment by any suitable means. In another embodiment, the compound of interest is attached to the linker by an amide bond, and the linker is attached to the C-terminus of the split intein C-fragment by an amide bond.
[0102] In another embodiment, the compound of interest is a protein having an N-terminal amino acid residue of an extein that can be spliced by an intein comprising a split intein C-terminal fragment of the sequence of SEQ ID NO: 7. In another particular embodiment, the compound of interest is a protein having at its N-terminus the sequence Cys-Xaa1-Xaa2 or Cys-Xaa1-Xaa2-Leu, wherein Xaa1 and Xaa2 are any amino acid; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is any amino acid; Xaa1 is any amino acid and Xaa2 is Gly, Glu, Ala, or Arg; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is Gly, Glu, Ala, or Arg.
[0103] In another embodiment, the compound of interest is a protein having at its N-terminus a sequence selected from Cys-Glu-Phe, Cys-Ala-Phe; Cys-Gly-Phe; Cys-Arg-Phe, Cys-Phe-Phe, Cys-Glu-Gly, Cys-Glu-Glu, Cys-Glu-Ala, Cys-Glu-Phe-Leu, Cys-Ala-Phe-Leu; Cys-Gly-Phe-Leu; Cys-Arg-Phe-Leu, Cys-Phe-Phe-Leu, Cys-Glu-Gly-Leu, Cys-Glu-Glu-Leu and Cys-Glu-Ala-Leu.
[0104] In another embodiment, when the compound of interest is not a protein, the C-intein comprises or consists of a polypeptide selected from the group consisting of SEQ ID NOs: 10 to 48 or SEQ ID NOs: 128 to 166. In another embodiment, when the compound of interest is not a protein, the compound of interest and the C-intein are linked via a linker, in which case the linker is a peptide having the N-terminal amino acid residues of an extein that can be spliced by an intein comprising a split intein C-terminal fragment of the sequence of SEQ ID NO: 7, and in a particular embodiment, the linker is a peptide having at its N-terminus the sequence Cys-Xaa1-Xaa2 or Cys-Xaa1-Xaa2-Leu, wherein Xaa1 and Xaa2 are any amino acid; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is any amino acid; Xaa1 is any amino acid and Xaa2 is Gly, Glu, Ala, or Arg; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is Gly, Glu, Ala, or Arg; Alternatively, the linker is a peptide having at its N-terminus a sequence selected from Cys-Glu-Phe, Cys-Ala-Phe, Cys-Gly-Phe, Cys-Arg-Phe, Cys-Phe-Phe, Cys-Glu-Gly, Cys-Glu-Glu, Cys-Glu-Ala, Cys-Glu-Phe-Leu, Cys-Ala-Phe-Leu, Cys-Gly-Phe-Leu, Cys-Arg-Phe-Leu, Cys-Phe-Phe-Leu, Cys-Glu-Gly-Leu, Cys-Glu-Glu-Leu and Cys-Glu-Ala-Leu.
[0105] In another embodiment, the compound of interest is a protein that does not have an N-terminal amino acid residue of an extein that can be spliced by an intein comprising a split C-intein of SEQ ID NO: 7, in which case (i) the C-intein comprises or consists of a polypeptide of a sequence of SEQ ID NO: 10 to 44 or 128 to 166, or (ii) the compound of interest and the C-intein are linked via a linker, in which case the linker is a peptide that has the C-terminal amino acid residue of an extein that can be spliced by an intein comprising a split intein C-terminal fragment of SEQ ID NO: 7, in a particular embodiment the linker is a peptide having the sequence Cys-Xaa1-Xaa2 or Cys-Xaa1-Xaa2-Leu at its N-terminus, in which Xaa1 and Xaa2 are any amino acid; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is any amino acid; Xaa1 is any amino acid and Xaa2 is Gly, Glu, Ala, or Arg; Xaa1 is Ala, Gly, Art, or Phe, and Xaa2 is Gly, Glu, Ala, or Arg; Alternatively, the linker is a peptide having at its N-terminus a sequence selected from Cys-Glu-Phe, Cys-Ala-Phe, Cys-Gly-Phe, Cys-Arg-Phe, Cys-Phe-Phe, Cys-Glu-Gly, Cys-Glu-Glu, Cys-Glu-Ala, Cys-Glu-Phe-Leu, Cys-Ala-Phe-Leu; Cys-Gly-Phe-Leu; Cys-Arg-Phe-Leu, Cys-Phe-Phe-Leu, Cys-Glu-Gly-Leu, Cys-Glu-Glu-Leu and Cys-Glu-Ala-Leu.
[0106] In certain embodiments, the compound of interest is a protein or polypeptide.
[0107] In another embodiment, the compound of interest is a protein greater than 25 KDa, greater than 50 KDa or greater than 100 KDa.
[0108] In certain embodiments, the protein is Cas9 or a fragment of Cas9. In certain embodiments, the compound of interest is a polypeptide or protein, and when the complex comprises a linker, the linker is a peptide linker. In this embodiment, the complex is a fusion protein.
[0109] In another embodiment, the polypeptide of interest is an antibody or a fragment of an antibody. In a particular embodiment, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In a particular embodiment, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In a particular embodiment, the compound of interest is the heavy chain of a mouse αDec205 monoclonal antibody, as described by Stevens et al., JACS 2016, 138: 2162-5.
[0110] In another embodiment, the compound of interest is a protein fragment, in particular embodiments, a protein fragment of greater than 25KDa, greater than 50KDa, or greater than 100KDa. In another embodiment, the compound of interest is a C-terminal fragment of a protein. The term "C-terminal fragment of a protein" as used herein refers to fragments of various lengths that include the C-terminus of a protein. In particular embodiments, the C-terminal fragment is a fragment that comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the length of the full-length protein.
[0111] In another embodiment, the compound of interest is an antibody, the term antibody having been described with respect to N-inteins and which applies equally in this case.
[0112] In certain embodiments, the complex comprises a split intein C-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120.
[0113] In certain embodiments, the sequences of SEQ ID NO:123 and 124 have higher temperature stability than the sequence of SEQ ID NO:7.
[0114] In certain embodiments, the complex comprises a split intein C-terminal fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 69-87, or a variant thereof. In certain embodiments, the variant is a functionally equivalent variant.
[0115] The terms "variant" and "functionally equivalent variant" have been defined previously. In certain embodiments, functionally equivalent variants of the split intein C-fragments of SEQ ID NOs: 69-87 have at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to the sequences from which they are derived.
[0116] In certain embodiments, functionally equivalent variants of the split intein C-fragments of SEQ ID NOs: 69-87 maintain or improve the activity of the sequences from which they are derived. The term "activity" as well as methods for measuring this activity have been previously defined for functionally equivalent variants of the split intein N-fragments of SEQ ID NO: 7. The embodiments relating to the activity of variants of the split intein C-fragments of SEQ ID NOs: 69-87 apply directly to the activity of variants of the split intein C-fragments of SEQ ID NOs: 69-87.
[0117] A complex comprising a split intein N-terminal fragment and a split intein C-terminal fragment In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: (iv) a split intein C-terminal fragment of the present disclosure or a split intein C-terminal fragment comprising a sequence selected from the group consisting of SEQ ID NOs: 114 to 120; (v) a compound of interest, and (vi) A split intein N-fragment of the present disclosure, or a split intein N-fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. A complex comprising: the conjugate optionally comprises a linker between (i) and (ii) and / or between (ii) and (iii); The compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond, or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond; The compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond, or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the N-terminus of the split intein N-fragment by an amide bond. Concerning the complex.
[0118] The terms "target compound" and "linker" are defined above with respect to the first conjugate of the present disclosure. All target compound and linker embodiments of the first conjugate of the present disclosure apply directly to the second conjugate of the present disclosure.
[0119] In certain embodiments, the compound of interest is a protein or polypeptide.
[0120] In another embodiment, the target compound is a protein larger than 25KDa, larger than 50KDa, or larger than 100KDa. In a particular embodiment, the target compound is a polypeptide or protein, and when the complex comprises a linker, the linker is a peptide linker. In this embodiment, the complex is a fusion protein.
[0121] In certain embodiments, the polypeptide of interest is an antibody or a fragment of an antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is the heavy chain of a murine αDEC-205 monoclonal antibody as described by Stevens et al., JACS 2016, 138: 2162-5.
[0122] In certain embodiments, the complex comprises a split intein C-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120.
[0123] In certain embodiments, the sequences of SEQ ID NO:123 and 124 have a higher temperature stability than the sequence of SEQ ID NO:7.
[0124] In certain embodiments, the complex comprises a split intein C-terminal fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 69 to 87, or a variant thereof. In certain embodiments, the variant is a functionally equivalent variant.
[0125] In certain embodiments, the complex comprises a split intein N-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 111, 112 and 113.
[0126] In certain embodiments, the sequences of SEQ ID NO:112 and 113 have a higher temperature stability than the sequence of SEQ ID NO:1.
[0127] In certain embodiments, the complex comprises a split intein N-fragment comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-68, or a variant thereof. In another embodiment, the variant is a functionally equivalent variant.
[0128] The terms "variant" and "functionally equivalent variant" have been defined above. The embodiments relating to these terms apply directly to the third complex of the present disclosure.
[0129] Compositions Comprising the Conjugates of the Disclosure In another aspect, the present disclosure relates to a composition comprising a first conjugate and a second conjugate of the present disclosure, hereinafter the first composition of the present disclosure.
[0130] The term "composition" is intended to encompass any product that contains the specified components, as well as any product that is obtained directly or indirectly from the combination of the specified components in the specified amounts. The components of the composition may be packaged together in a single formulation, or may be packaged separately in different formulations. Thus, in one embodiment, the first complex of the present disclosure is packaged together with the second complex of the present disclosure in a single formulation. In another embodiment, the first complex of the present disclosure and the second complex of the present disclosure are packaged separately.
[0131] In one embodiment, the first complex and the second complex comprise an N-terminal fragment and a C-terminal fragment, respectively, of the same protein in such a manner that when both complexes are combined according to the methods of the present disclosure, the N-terminal fragment of the protein is linked to the C-terminal fragment of that protein to generate a full-length protein.
[0132] Conjugates of the present disclosure In another aspect, the present disclosure relates to a conjugate comprising a first conjugate of the disclosure and a second conjugate of the disclosure, hereinafter the first conjugate of the disclosure, wherein the C-terminus of the split intein N-fragment is linked to the N-terminus of the split intein C-fragment by a peptide bond.
[0133] In another aspect, the present disclosure relates to a conjugate comprising (a) a first conjugate of the present disclosure, and (b) a split intein C-fragment comprising the amino acid sequence of SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity to SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120, wherein the C-terminus of the split intein N-fragment is linked to the N-terminus of the split intein C-fragment by a peptide bond, hereinafter the second conjugate of the present disclosure.
[0134] In certain embodiments, the conjugate comprises a split intein C-fragment comprising or consisting of a sequence selected from SEQ ID NOs: 121-124.
[0135] In certain embodiments, the conjugate comprises a split intein C-fragment comprising or consisting of a sequence selected from SEQ ID NOs: 69-87 or a variant thereof. In certain embodiments, the variant is a functionally equivalent variant. Functionally equivalent variants of the split intein C-fragments of SEQ ID NOs: 69-87 have been defined previously.
[0136] In certain embodiments, the compound of interest is a protein or polypeptide.
[0137] In another embodiment, the compound of interest is a protein greater than 25 KDa, greater than 50 KDa or greater than 100 KDa.
[0138] In certain embodiments, the protein is Cas9 or a fragment of Cas9.
[0139] In certain embodiments, the compound of interest is a polypeptide or a protein, and when the conjugate comprises a linker, the linker is a peptide linker.
[0140] In certain embodiments, the polypeptide of interest is an antibody or a fragment of an antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is the heavy chain of a murine αDEC-205 monoclonal antibody as described by Stevens et al., JACS 2016, 138: 2162-5.
[0141] Polynucleotides, Vectors and Host Cells of the Disclosure In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: a split intein N-fragment of the present disclosure, or A split intein C-fragment of the present disclosure, or a first, second or third conjugate of the present disclosure, where the compound of interest is a polypeptide or protein and the linker, if present, is a peptide linker; or Conjugates of the present disclosure The present invention relates to a polynucleotide encoding
[0142] As used herein, the term "polynucleotide" refers to a polymer composed of multiple nucleotide units (deoxyribonucleotides or ribonucleotides, or related structural variants or synthetic analogues thereof) linked via phosphodiester bonds (or related structural variants or synthetic analogues thereof). The term polynucleotide includes double-stranded or single-stranded genomic and cDNA, RNA, any synthetic and engineered polynucleotide, and both sense and antisense polynucleotides (only the sense strand is disclosed in this disclosure). It includes single-stranded and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids.
[0143] The polynucleotides of the present disclosure are found in isolated form or as part of a vector that allows for the amplification of said polynucleotides in a suitable host cell. Thus, in another aspect, the present disclosure relates to a vector comprising a polynucleotide of the present disclosure as described above.
[0144] Suitable vectors for insertion of said polynucleotides are prokaryotic expression vectors such as pUC18, pUC19, Bluescript and its derivatives, mpl8, mpl9, pBR322, pMB9, ColEl, pCRl, RP4; phage and "shuttle" vectors such as pSA3 and pAT28; yeast expression vectors, such as vectors of the type 2 micron plasmid, integrative plasmids, YEP vectors, centromeric plasmids, etc.; insect cell expression vectors such as the pAC and pVL series of vectors; plant expression vectors such as pIBI, pEarleyGate, pAVA, pCAMBIA, pGSA, pGWB, pMDC, pMY, pORE series; and vectors derived from eukaryotic expression vectors, including baculoviruses suitable for infecting insect cells using any commercially available baculovirus system. Vectors for eukaryotic cells include viral vectors (adenovirus, adeno-associated virus (AAV), retrovirus and lentivirus) and non-viral vectors such as pSilencer 4.1-CMV (Ambion), pcDNA3, pcDNA3.1 / hyg, pHMCV / Zeo, pCR3.1, pEFI / His, pIND / GS, pRc / HCMV2, pSV40 / Zeo2, pTRACER-HCMV, pUB6 / V5-His, pVAXl, pZeoSV2, pCI, pSVL and PKSV-10, pBPV-1, pML2d and pTDTl.
[0145] The vector may also comprise a reporter or marker gene which makes it possible to identify cells which have incorporated the vector after contacting them with it.
[0146] Reporter genes useful in the context of the present disclosure include lacZ, luciferase, thymidine kinase, GFP, and the like. Marker genes useful in the context of the present invention include, for example, the neomycin resistance gene, which confers resistance to the aminoglycoside G418; the hygromycin phosphotransferase gene, which confers resistance to hygromycin; the ODC gene, which confers resistance to inhibitors of ornithine decarboxylase (2-(difluoromethyl)-DL-ornithine (DFMO); the dihydrofolate reductase gene, which confers resistance to methotrexate; the puromycin-N-acetyltransferase gene, which confers resistance to puromycin; the ble gene, which confers resistance to zeocin; the adenosine deaminase gene, which confers resistance to 9-β-D-xylofuranose adenine; the cytosine deaminase gene, which allows cells to grow in the presence of N-(phosphonacetyl)-L-aspartic acid; and the thymidine kinase gene, which allows cells to grow in the presence of aminopterin. Genes that can be used include the xanthine-guanine phosphoribosyltransferase gene, which allows cells to grow in the presence of xanthine and in the absence of guanine; the trpB gene of E. coli, which allows cells to grow in the presence of indole instead of tryptophan; and the hisD gene of E. coli, which allows cells to use histidinol instead of histidine. The selection gene is incorporated into a plasmid that may additionally contain a promoter (e.g., CMV or SV40 promoter) suitable for the expression of the gene in eukaryotic cells, an optimal translation initiation site (e.g., the so-called Kozak rule site or IRES), a polyadenylation site, e.g., the SV40 polyadenylation or phosphoglycerate kinase site, an intron, e.g., the β-globulin gene intron. Alternatively, it is also possible to use a combination of both reporter and marker genes simultaneously in the same vector.
[0147] On the other hand, as known by those skilled in the art, the choice of vector depends on the host cell into which it is then introduced. By way of example, the vector into which the polynucleotide is introduced may be a yeast artificial chromosome (YAC), a bacterial artificial chromosome (BAC) or a PI-derived artificial chromosome (PAC). The characteristics of YAC, BAC and PAC are known to those skilled in the art. Detailed information on the above types of vectors is provided, for example, by Giraldo and Montoliu (Giraldo, P. & Montoliu L., 2001 Size matters: use of YACs, BACs and PACs in transgenic animals, Transgenic Research 10(2): 83-110). The vector of the present disclosure can be obtained by conventional methods known to those skilled in the art (Sambrook J. et al., 2000 "Molecular cloning, a Laboratory Manual", 3rd ed., Cold Spring Harbor Laboratory Press, NY Vol 1-3).
[0148] The polynucleotides of the present disclosure can be introduced into host cells in vivo as naked DNA plasmids and with vectors by methods known in the art, including but not limited to transfection, electroporation (e.g., transdermal electroporation), microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, using a gene gun, or using a DNA vector transporter. Methods for formulating and administering naked DNA to mammalian muscle tissue are also known. See Feigner P et al., U.S. Patent Nos. 5,580,859 and 5,589,466. Other molecules, such as cationic oligopeptides, peptides derived from DNA-binding proteins, or cationic polymers, are also useful for promoting transfection of nucleic acids in vivo. See Bazile D et al., WO1995021931, and Byk G et al., WO1996025508.
[0149] Another well-known method that can be used to introduce polynucleotides into host cells is particle bombardment (aka biolistic transformation). Biolistic transformation is generally accomplished in one of several ways. One common method involves firing inert or biologically active particles at cells. See Sanford J et al., U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792.
[0150] Alternatively, vectors can be introduced in vivo by lipofection. The use of cationic lipids can promote the encapsulation of negatively charged nucleic acids and can also promote fusion with negatively charged cell membranes. See Feigner P, Ringold G, Science 1989; 337:387-388. Useful lipid compounds and compositions for the introduction of nucleic acids have been described. See Feigner P et al., U.S. Patent No. 5,459,127; Behr J et al., WO1995018863; and Byk G, WO1996017823.
[0151] Thus, in another aspect, the present disclosure relates to host cells comprising the polynucleotides or vectors of the present disclosure. These cells can be obtained by conventional methods known to those skilled in the art (see, for example, Sambrook et al., cited above).
[0152] The term "host cell" as used herein refers to a cell into which a nucleic acid of the present disclosure, such as a polynucleotide or vector according to the present disclosure, can be introduced and express a split intein N-terminal fragment of the present disclosure or a fusion protein comprising said split intein N-terminal fragment. The terms "host cell" and "recombinant host cell" are used interchangeably herein. They should be understood to refer not only to the specific cell of interest, but also to the progeny or potential progeny of such a cell. Since certain modifications may occur in subsequent generations due to either mutation or environmental influences, such progeny may not actually be identical to the parent cell, but are still included within the scope of the term as used herein. The term includes any cultured cell that can be modified by the introduction of heterologous DNA. In certain embodiments, the host cell is one in which the polynucleotide of the present disclosure can be stably expressed, post-translationally modified, localized to the appropriate intracellular compartment, and associated with the appropriate transcriptional machinery. The selection of the appropriate host cell is also influenced by the selection of the detection signal. For example, the reporter construct can provide a selectable or screenable trait upon activation or inhibition of gene transcription in response to a transcriptional regulatory protein, as described above, and the host cell phenotype is taken into consideration to achieve optimal selection or screening. Host cells of the present disclosure include prokaryotic and eukaryotic cells. Prokaryotes include gram-negative or gram-positive organisms, such as E. coli or bacilli. It is understood that in certain embodiments, prokaryotic cells are used to amplify the transcriptional control sequence comprising the polynucleotide or vector of the present disclosure. Suitable prokaryotic host cells for transformation include, for example, E. coli, Bacillus subtilis, Salmonella typhimurium, and various species of Pseudomonas, Streptomyces, and Staphylococcus.Eukaryotic cells include, but are not limited to, yeast cells, plant cells, fungal cells, insect cells (e.g., baculovirus), mammalian cells, and parasitic cells, such as trypanosomes. As used herein, yeast includes yeast in the strict taxonomic sense, i.e., unicellular organisms, as well as filamentous yeast-like multicellular fungi. Exemplary species include Kluyverei lactis, Schizosaccharomyces pombe, and Ustilaqo maydis, as well as Saccharomyces cerevisiae. Other yeasts that can be used in the practice of the present disclosure include Neurospora crassa, Aspergillus niger, Aspergillus nidulans, Pichia pastoris, Candida tropicalis, and Hansenula polymorpha. Mammalian host cell culture systems include established cell lines such as COS cells, L cells, 3T3 cells, Chinese hamster ovary (CHO) cells, embryonic stem cells, BHK, HeK, or HeLa cells. In certain embodiments, eukaryotic cells are used for recombinant gene expression.
[0153] Method for conjugating two compounds of interest In another aspect, the present disclosure provides a method for obtaining a conjugate between a first compound of interest and a second compound of interest, the method comprising: (i) (a) a first complex of the present disclosure comprising a first compound of interest and a split intein N-terminal fragment comprising the amino acid sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO: 1, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110; (b) a second complex of the present disclosure comprising a second compound of interest and a split intein C-terminal fragment comprising the amino acid sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity to SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120; or A complex comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof and a second compound of interest, optionally comprising a linker between said split intein C-terminal fragment and said second compound of interest, the second compound of interest is attached to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the second compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond. under conditions suitable for combining the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between the first compound of interest and the second compound of interest. The present invention relates to a method comprising the steps of:
[0154] In another aspect, the present disclosure provides a method for obtaining a conjugate between a first compound of interest and a second compound of interest, the method comprising: (i) (a) a first complex of the present disclosure comprising a first compound of interest and a split intein N-terminal fragment comprising the amino acid sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO:1, or an amino acid sequence selected from the group consisting of SEQ ID NOs:103-110; or A complex comprising a compound of interest and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, optionally comprising a linker between said compound of interest and the split intein N-terminal fragment, the target compound is linked to the N-terminus of the split intein N-fragment by an amide bond, or a conjugate, wherein if said conjugate comprises a linker, said compound of interest is attached to the linker by an amide bond and / or said linker is attached to the N-terminus of the split intein N-fragment by an amide bond; (b) the complex according to any one of claims 17 to 21, comprising a second compound of interest and a split intein C-terminal fragment comprising the amino acid sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120. under conditions suitable for combining the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between the first compound of interest and the second compound of interest. The present invention relates to a method comprising the steps of:
[0155] The term "AceL-TerL intein" as used herein refers to a family of non-canonical split inteins identified in Lake Ace, a permanently stratified salt lake in Antarctica. Inteins of this family are described by Thiel et al., Angew. Chem. Int. Ed 2014, 53: 1306-1310. In certain embodiments, the AceL-TerL split intein N-terminal fragment comprises or consists of the sequence of SEQ ID NO: 101 or 102. In certain embodiments, the AceL-TerL split intein C-terminal fragment comprises or consists of the sequence of SEQ ID NO: 99 or 100.
[0156] The terms "compound of interest" and "functionally equivalent variant" have been described previously. In some embodiments, the first compound and / or the second compound is or comprises a peptide or polypeptide. In some embodiments, the first compound and / or the second compound is or comprises an antibody, an antibody chain, or an antibody heavy chain. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is the heavy chain of a mouse αDEC-205 monoclonal antibody as described in Stevens et al., JACS 2016, 138: 2162-5.
[0157] In some embodiments, the first compound and / or the second compound is or comprises a peptide, an oligonucleotide, a drug, or a cytotoxic molecule.
[0158] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 111-113.
[0159] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68, or a functionally equivalent variant thereof.
[0160] In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 121 to 124. In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69 to 87, or a functionally equivalent variant thereof.
[0161] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68 or a functionally equivalent variant thereof, and the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69-87 or a functionally equivalent variant thereof.
[0162] Suitable conditions for combining the split intein N-fragment and the split intein C-fragment to form an intein intermediate can be readily determined by one of skill in the art. In certain embodiments, these conditions include contacting the first complex with the second complex at a temperature between 0°C and 70°C, e.g., between 5°C and 65°C, between 10°C and 60°C, between 15°C and 55°C, between 20°C and 50°C, between 25°C and 45°C, between 30°C and 40°C, between 25°C and 35°C, between 45°C and 55°C, and in certain embodiments, at 30°C or 50°C. In another embodiment, these conditions include contacting the first complex with the second complex at a pH of 0.1 to 14, e.g., 0.5 to 13.5, 1.0 to 13.0, 1.5 to 12.5, 2.0 to 12.0, 2.5 to 11.5, 3.0 to 11.0, 3.5 to 10.5, 4.0 to 10.0, 4.5 to 9.5, 5.0 to 9.0, 5.5 to 8.5, 6.0 to 8.0, 6.5 to 7.5, and in certain embodiments, at pH 7.2. In another embodiment, these conditions include contacting the first complex with the second complex in the absence of urea or in the presence of urea at a concentration of 1 M to 5 M, e.g., 1.5 M to 4.5 M, 2 M to 4.0 M, 2.5 M to 3.5 M, and in certain embodiments, at 2 M urea or 4 M urea. In certain embodiments, these conditions include contacting the first complex with the second complex at a temperature of 50° C., pH 7.2, and in the presence of urea 2 M or urea 4 M. All possible combinations of temperature, urea concentration, and pH are also contemplated by the present invention.
[0163] Methods for obtaining conjugates of target compounds with nucleophiles In another aspect, the present disclosure provides a method for obtaining a conjugate of a target compound and a nucleophile, comprising: (i) (a) a first complex of the present disclosure, wherein the split intein N-terminal fragment comprises the amino acid sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NO: 1, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110; or A complex comprising a compound of interest and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, optionally comprising a linker between said compound of interest and the split intein N-terminal fragment, the target compound is linked to the N-terminus of the split intein N-fragment by an amide bond, or a conjugate, wherein if said conjugate comprises a linker, said compound of interest is attached to the linker by an amide bond and / or said linker is attached to the N-terminus of the split intein N-fragment by an amide bond; (b) a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 9, 23 to 48, and 141 to 166; under suitable conditions to allow binding between the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) contacting the intein intermediate with an exogenous nucleophile; The present invention relates to a method comprising the steps of:
[0164] The terms "AceL-TerL split intein N-fragment", "compound of interest" and "functionally equivalent variant" have been defined previously. In certain embodiments, the AceL-TerL split intein N-fragment comprises or consists of the sequence of SEQ ID NO: 101 or 102. In some embodiments, the first compound and / or the second compound is or comprises a peptide or polypeptide. In some embodiments, the first compound and / or the second compound is or comprises an antibody, an antibody chain, or an antibody heavy chain. In certain embodiments, the polypeptide of interest is an antibody or an antibody fragment. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is the heavy chain of a mouse αDEC-205 monoclonal antibody as described in Stevens et al., JACS 2016, 138: 2162-5.
[0165] In some embodiments, the first compound and / or the second compound is or comprises a peptide, an oligonucleotide, a drug, or a cytotoxic molecule.
[0166] The term "nucleophile," as used herein, refers to any chemical species that donates an electron pair to an electrophile to form a chemical bond in connection with a reaction. Any molecule or ion with a free electron pair or at least one pi bond can act as a nucleophile. Because nucleophiles donate electrons, they are by definition Lewis bases. In one embodiment of the present disclosure, the nucleophile can be either a sulfur nucleophile or a nitrogen nucleophile.
[0167] The term "sulfur nucleophile" as used herein refers to a nucleophile comprising at least one sulfur atom. Examples of sulfur nucleophiles include hydrogen sulfide and its salts, thiols (RSH), thiolate anions (RS-), anions of thiol carboxylic acids (RC(O)-S-), and anions of dithiocarbonates (RO-C(S)-S-) and dithiocarbamates (R 2N-C(S)-S-). In one embodiment of the present disclosure, the sulfur nucleophile is mesna or DTT.
[0168] The term "nitrogen nucleophile" as used herein refers to a nucleophile that comprises at least one nitrogen atom. Nitrogen nucleophiles include ammonia, azides, amines, hydrazines, and nitrites. In one embodiment of the present disclosure, the nitrogen nucleophile is hydrazine.
[0169] The term "exogenous nucleophile" as used herein means that the nucleophile is not part of the complex or split intein C-fragment of the present disclosure.
[0170] Thus, in this method, the target compound is a protein or polypeptide, and the intein intermediate is reacted with a nucleophile to release the target polypeptide from the bound intein N-terminal and C-terminal fragments, thereby obtaining a protein or polypeptide with a C-terminus modified by a nucleophile. This type of modification depends on the type of nucleophile. For example, if the nucleophile is a thiol, the modified target polypeptide is an α-thioester, which can then be further modified with, for example, a variety of nucleophiles (e.g., drugs, polymers, another polypeptide, oligonucleotides), or any other moiety using well-known α-thioester chemistry for protein modification at the C-terminus. One advantage of this chemical method is that only the C-terminus is modified with a thioester for further modification, thus allowing selective modification only at the C-terminus and not other acidic residues in the polypeptide. If the target compound is not a protein or polypeptide, the target compound has a moiety that can react with a nucleophile, i.e., an electrophile. Suitable electrophiles that can react with a nucleophile are generally known in the art.
[0171] In certain embodiments, the nucleophile is added to the reaction after contacting the first complex of the present disclosure with the split intein C-fragment, hi another embodiment, the first complex of the present disclosure, the split intein C-fragment, and the nucleophile are contacted simultaneously.
[0172] In certain embodiments, the method further comprises contacting the conjugate of the target compound and the nucleophile with a second exogenous nucleophile.
[0173] The nucleophile used in the methods disclosed herein with the intein intermediate or as a subsequent or second nucleophile to react with, for example, an α-thioester may be any compound or material having a suitable nucleophilic moiety. For example, to form a thioester, a thiol moiety is contemplated as the nucleophile. In some cases, the thiol is a 1,2 aminothiol, or a 1,2-aminoselenol. An α-selenothioester can be formed by using a selenothiol (R-SeH). Other contemplated nucleophiles include amines (i.e., aminolysis to directly obtain amides), hydrazines (to obtain hydrazides), and amino-oxy groups (to provide hydroxamic acids). Additionally, the nucleophile may be a functional group within the compound of interest for conjugation to a polypeptide of interest (e.g., a drug to form a protein-drug conjugate) or may alternatively bear an additional functional group for subsequent known bioorthogonal reactions, such as an azide or alkyne (for the formation of a triazole by click chemistry reaction between two functional groups), a tetrazole, an a-keto acid, an aldehyde or ketone, or a cyanobenzothiazole.
[0174] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 111-113.
[0175] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68, or a functionally equivalent variant thereof.
[0176] Compositions Comprising Polynucleotides In another aspect, the present disclosure provides a method for producing a method for manufacturing a semiconductor device comprising: (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO:1 or a variant thereof having at least 90% sequence identity with SEQ ID NO:1, or an amino acid sequence selected from the group consisting of SEQ ID NOs:103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a variant thereof, or a sequence according to SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a variant thereof, or a sequence of SEQ ID NO: 1 or a variant thereof having at least 90% sequence identity with SEQ ID NO: 1, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising A composition comprising:
[0177] In certain embodiments, the variants are functionally equivalent variants.
[0178] The term "composition" has been previously defined. In certain embodiments, the first polynucleotide is packaged together with the second polynucleotide as a single formulation. In other embodiments, the first polynucleotide and the second polynucleotide are packaged separately.
[0179] The term "AceL-TerL intein" has been previously defined. In certain embodiments, the AceL-TerL split intein N-fragment comprises or consists of the sequence of SEQ ID NO: 101 or 102. In certain embodiments, the AceL-TerL split intein C-fragment comprises or consists of the sequence of SEQ ID NO: 99 or 100.
[0180] In certain embodiments, the first polypeptide of interest is an N-terminal fragment of a protein and the second polypeptide of interest is a C-terminal fragment of said protein, in certain embodiments a protein greater than 25 KDa, greater than 50 KDa or greater than 100 KDa, such that covalent linking of the C-terminus of the first polypeptide of interest with the N-terminus of the second polypeptide of interest results in a full-length protein.
[0181] In some embodiments, the first compound and the second compound are or include an antibody, an antibody chain, or an antibody heavy chain. In certain embodiments, the polypeptide of interest is an antibody or an antibody fragment. In certain embodiments, the polypeptide of interest is a heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is a heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is a heavy chain of a mouse αDEC-205 monoclonal antibody as described in Stevens et al., JACS 2016, 138: 2162-5.
[0182] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 111-113.
[0183] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68, or a functionally equivalent variant thereof.
[0184] In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 121-124.
[0185] In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69-87, or a functionally equivalent variant thereof.
[0186] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68 or a functionally equivalent variant thereof, and the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69-87 or a functionally equivalent variant thereof.
[0187] The second composition of the present disclosure can be used to express a gene of interest in a cell using the methods of the present disclosure.
[0188] Methods for expressing a gene of interest In another aspect, the present disclosure provides a method for expressing a gene of interest in a cell, hereinafter A first method for expressing a gene of interest, comprising: (i) The cell (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% thereof, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, or a sequence according to SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (a) From the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, or a split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% of the sequence, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. a first polynucleotide encoding a first fusion protein comprising: (b) From the N-terminus to the C-terminus, a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functional variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising contacting the (ii) expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced; and (iii) contacting the first fusion protein with the second fusion protein such that the split intein N-terminal fragment binds to the split intein C-terminal fragment to form an intein intermediate, and such that the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest and the N-terminus of the second polypeptide of interest. The present invention relates to a method comprising the steps of:
[0189] In another aspect, the present disclosure provides a method for expressing a gene of interest, comprising: (i) The first cell is subjected to a step of, from the N-terminus to the C-terminus: a first polypeptide of interest, and A split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% thereof, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. with a first polynucleotide encoding a first fusion protein comprising a signal peptide; (ii) the second cell is transfected with, from the N-terminus to the C-terminus: A split intein C-terminal fragment comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, or a sequence according to SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest with a second polynucleotide encoding a second fusion protein comprising a signal peptide; or, (i) dividing the first cell into two cells, from the N-terminus to the C-terminus, a first polypeptide of interest, and AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, or a split intein N-terminal fragment comprising the sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% of the sequence, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. with a first polynucleotide encoding a first fusion protein comprising a signal peptide; (ii) the second cell is transfected with, from the N-terminus to the C-terminus: a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest with a second polynucleotide encoding a second fusion protein comprising a signal peptide; (iii) expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced and secreted; and (iv) contacting the first fusion protein with the second fusion protein such that the split intein N-terminal fragment binds to the split intein C-terminal fragment to form an intein intermediate, and the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest and the N-terminus of the second polypeptide of interest; The present invention relates to a method comprising the steps of:
[0190] The term "AceL-TerL intein" has been previously defined. In certain embodiments, the AceL-TerL split intein N-fragment comprises or consists of the sequence of SEQ ID NO: 101 or 102. In certain embodiments, the AceL-TerL split intein C-fragment comprises or consists of the sequence of SEQ ID NO: 99 or 100.
[0191] In certain embodiments, the first polypeptide of interest is an N-terminal fragment of a protein and the second polypeptide of interest is a C-terminal fragment of said protein, in certain embodiments a protein of greater than 25 KDa, greater than 50 KDa or greater than 100 KDa such that covalent linking of the C-terminus of the first polypeptide of interest with the N-terminus of the second polypeptide of interest results in a full-length protein.
[0192] In certain embodiments, the first polypeptide of interest or the second polypeptide of interest is Cas9 or a fragment of Cas9. In certain embodiments, the first polypeptide of interest is an N-terminal fragment of Cas9 and the second polypeptide of interest is a C-terminal fragment of Cas9. In another embodiment, when the first polypeptide of interest is an N-terminal fragment of Cas9 and the second polypeptide of interest is a C-terminal fragment of Cas9, the C-terminus of the N-terminal fragment of Cas9 and the N-terminus of the C-terminal fragment of Cas9 are covalently linked to obtain a full-length Cas9 protein.
[0193] In some embodiments, the first compound and / or the second compound is or comprises an antibody, an antibody fragment, an antibody chain, or an antibody heavy chain. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 antibody. In certain embodiments, the polypeptide of interest is the heavy chain of an anti-DEC-205 monoclonal antibody. In certain embodiments, the compound of interest is the heavy chain of a mouse αDEC-205 monoclonal antibody as described in Stevens et al., JACS 2016, 138: 2162-5.
[0194] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 111-113.
[0195] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68, or a functionally equivalent variant thereof.
[0196] In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 121-124.
[0197] In certain embodiments, the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69-87, or a functionally equivalent variant thereof.
[0198] In certain embodiments, the split intein N-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 49-68 or a functionally equivalent variant thereof, and the split intein C-fragment comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 69-87 or a functionally equivalent variant thereof.
[0199] The contacting of the cell with the first polynucleotide and / or the second polynucleotide can be carried out by any suitable means that allows the introduction of the target polynucleotide into the cell, such as, for example, transfection, electroporation, microinjection, transduction, lipofection, cell fusion, DEAE dextran, calcium phosphate precipitation, using a gene gun, or using a DNA vector transporter.In the first method for expressing the target gene of the present disclosure, the cell can be contacted with the first polynucleotide and the second polynucleotide simultaneously, or the first polynucleotide and the second polynucleotide sequentially in any order, i.e., the cell can be contacted with the first polynucleotide first and then with the second polynucleotide, or the second polynucleotide first and then with the first polynucleotide.
[0200] Any cell previously defined as a host cell can be used in these methods.
[0201] The term "signal peptide" or "secretory signal peptide", as used herein, refers to a relatively short peptide, generally 5-30 amino acid residues long, that directs a protein synthesized within a cell to the secretory pathway. Signal peptides usually contain a stretch of hydrophobic amino acids that adopt a secondary alpha-helical structure. In addition, many peptides contain a stretch of amino acids with a positive charge that may contribute to the protein adopting a topology favorable for its translocation. Signal peptides tend to have a motif at their carboxyl terminus for recognition by peptidases, which can hydrolyze the signal peptide to yield a free signal peptide and a mature protein. The signal peptide can be cleaved once the protein of interest has reached the appropriate location. Any secretory signal peptide can be used in the present disclosure.
[0202] In certain embodiments, the signal peptide is linked to the N-terminus of the first polypeptide of interest in the first fusion protein.
[0203] In certain embodiments, the signal peptide is linked to the N-terminus of the split intein C-fragment in the second fusion protein.
[0204] The present invention is illustrated by the following examples, which should not be construed as limiting the scope of the disclosure but are merely illustrative. EXAMPLES
[0205] material and method material Oligonucleotides and synthetic genes were purchased from Integrated DNA Technologies (Coralville, IA). Pfu Ultra II Hotsart fusion polymerase for cloning was purchased from Agilent (La Jolla, CA). All restriction enzymes and 2x Gibson Assembly Master Mix were purchased from New England Biolabs (Ipswich, MA). Highly competent cells used for cloning and protein expression were generated from One Shot Bl21(DE3) chemically competent E. coli and subcloning efficiency DH5α competent cells purchased from Invitrogen (Carlsbad, CA). DNA purification kits were purchased from Qiagen (Valencia, CA). All plasmids were sequenced by GENEWIZ (South Plainfield, NJ). Luria Bertani (LB) medium, and all buffer salts were purchased from Fisher Scientific (Pittsburgh, PA). Dimethylformamide (DMF), dichloromethane (DCM), Coomassie brilliant blue, triisopropylsilane (TIS), β-mercaptoethanol (BME), DL-dithiothreitol (DTT), sodium 2-mercaptoethanesulfonate (mesna), 5(6)-carboxyfluorescein, and thermolysin were purchased from Sigma-Aldrich (Milwaukee, WI). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and isopropyl-β-D-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. Louis, MO). Roche Complete protease inhibitor (Roche, Branchburg, NJ) was used for protein purification. Nickel-nitrilotriacetic acid (Ni-NTA) resin was purchased from Thermo scientific (Rockford, IL). Fmoc amino acids were purchased from Novabiochem (Darmstadt, Germany) or Bachem (Torrance, Calif.).O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) was purchased from Genscript (Piscatawas, NJ). Trifluoroacetic acid (TFA) was purchased from Halocarbon (North Augusta, SC). MES-SDS running buffer was purchased from Boston Bioproducts (Ashland, MA).
[0206] device Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on Hewlett-Packard 1100 and 1200 series machines equipped with a C18 Vydac column (5 μm, 4.6 × 150 mm). For all HPLC analyses, the following solvents were used at a flow rate of 1 mL / min: 0.1% TFA (trifluoroacetic acid) in water (solvent A) and 90% acetonitrile in water containing 0.1% TFA (solvent B). All peptides and proteins were analyzed using a gradient: 0% B 2 min, followed by 0–73% B 30 min. Electrospray ionization mass spectrometry (ESI-MS) was performed on a Bruker Daltonics MicroTOF-Q II mass spectrometer. Size exclusion chromatography (SEC) was performed on an AKTA FPLC system (GE Healthcare) using a Superdex S75 16 / 60 column (125 mL column volume) for preparative runs and a Superdex S75 10 / 300 column for analytical runs. Gels were imaged using a LI-COR Odyssey infrared imager. Circular dichroism experiments were performed on a Chirascan circular dichroism spectrometer (Applied Photophysics). Cell lysis was performed using an S-450D Branson Digital Sonifier. NMR experiments were performed on Bruker 900, 800, 600 and 500 MHz spectrometers equipped with a 5 mm TCI triple resonance cryoprobe. Steady-state fluorescence measurements were performed on a Horiba Floumax 4 fluorometer. Stopped-flow anisotropy measurements were performed on an Applied Photophysics SX20 stopped-flow spectrometer.
[0207] Consensus protein design Homologs of AceL TerL were identified by BLAST searches of metagenomic data in the NCBI (nucleotide collection) and JGI databases using the TerL DNA sequence. This identified TerL N- and C-inteins with high sequence identity to AceL (Table 1). Because it was not possible to match the cognate N- and C-inteins, the split inteins were treated as two different data sets and analyzed separately. The MSAs of these split inteins were then analyzed using Jalview 4 and a consensus sequence was determined. At some positions in the N-intein, additional residues from the alignment that correspond to loops not present in AceL were included in the consensus sequence.
[0208] [Table 1] TIFF0007579844000002.tif254161TIFF0007579844000003.tif253161TIFF0007579844000004.tif105164
[0209] Recombinant DNA cloning The synthetic genes were purchased and introduced into the pET-30 expression vector using Gibson assembly. Targeted mutations were introduced using inverse PCR with Pfu Ultra II HF polymerase. The identity of all recombinant plasmids was confirmed by sequencing, and the corresponding protein sequences are shown in Table 2.
[0210] [Table 2] TIFF0007579844000006.tif248166TIFF0007579844000007.tif160169
[0211] Expression and purification of inteins for splicing assays Intein expression and purification were performed as previously described. The expressed N-intein construct contained the following structure: His6-SUMO-MBP-EFE-Int N , where “His6” is a 6× polyhistidine affinity tag, “SUMO” is the ubiquitin-like protein SMT3, “MBP” is maltose-binding protein, “EFE” is the wild-type-1, -2, and -3 N-extein sequences of the TerL intein, and “Int N is the N-intein. The expressed C-intein construct contained the following structure: His 6 -SUMO-Int C -CEFL-GFP , where "Int C " is the C-intein, "CEFL" is the +1, +2, +3, and +4 C-extein residues of the TerL intein, and "GFP" is green fluorescent protein. For extein-dependence screening, constructs corresponding to each point mutation shown in the "EFE" or "CEFL" extein sequences were used.
[0212] E. coli BL21(DE3) cells were transfected with MBP-Int N or Int C The cultures were transformed with the -GFP intein plasmid and grown at 37°C in 1 L of LB containing 50 μg / mL kanamycin. The cultures reached OD 600 When the β-catenin binding protein (β-catenin) reached 0.6, 0.5 mM IPTG was added to induce expression (final concentration 0.5 mM, 18°C for 18 hours). C For test expression of the constructs, expression tests were also performed upon addition of IPTG for 3 hours at 37° C. After expression, cells were pelleted by centrifugation (5,000 rcf, 30 min) and stored at −80° C.
[0213] The cell pellet was then resuspended in 30 mL of lysis buffer (50 mM phosphate, 300 mM NaCl, 5 mM imidazole, pH 8.0) containing a protease inhibitor cocktail. The cells were lysed by sonication (35% amplitude, 8 x 20 sec pulses on / 30 sec off) and then pelleted by centrifugation (35,000 rcf, 30 min). The supernatant was incubated with 4 mL of Ni-NTA resin at 4 °C for 30 min to bind the His-tagged inteins. The slurry was then loaded onto a fritted column, the flow-through was collected, and the column was filled with 20 mL of lysate. The column was then washed with lysis buffer for 10 min, and the protein was then eluted from the column with 20 mL of elution buffer (lysis buffer + 250 mM imidazole).
[0214] The eluted protein was dialyzed against lysis buffer and treated with 10 mM TCEP and Ulp1 protease overnight at 4 °C to cleave the His6-SUMO expression tag. The dialyzed protein was then incubated with 4 mL Ni-NTA resin for 30 min at 4 °C, after which it was applied to a fritted column and the flow-through was collected together with a 10 mL lysis buffer wash. The protein was then treated with 10 mM TCEP, concentrated to 2 mL, and purified on an S75 16 / 60 gel filtration column using degassed splicing buffer (100 mM sodium phosphate, 150 mM NaCl, 1 mM EDTA, pH 7.2) as the mobile phase. Fractions were analyzed by analytical RP-HPLC and ESI-MS (Figure 1, Table 3) and either used immediately in splicing assays or flash frozen in liquid nitrogen followed by long-term storage in glycerol (20% v / v).
[0215] [Table 3]
[0216] Splicing assay The splicing assay was performed according to a previously described protocol. 8Briefly, N-intein and C-intein (4 μM Intein) were used. N , 4μM Int C ) were individually preincubated for 15 min in splicing buffer (100 mM sodium phosphate, 150 mM NaCl, 1 mM EDTA, pH 7.2) containing 2 mM TCEP. Splicing reactions were carried out at the indicated temperatures and urea concentrations. For extein characterization, Cat C -GFP and MBP-Cat N Proteins were spliced with their cognate wild-type N-intein or C-intein at 30°C. Cat and AceL in the presence of urea * Splicing was carried out at 30°C. Splicing was initiated by mixing equal volumes of N-intein and C-intein, and aliquots were removed at the indicated times and quenched by adding 1:1 4x loading dye (160 mM Tris, 40% glycerol, 4% SDS, 0.08% bromophenol blue, 8% BME). Samples were analyzed by SDS-PAGE gel electrophoresis (12% Bis-Tris, 60 min, 150v) and quantified by densitometry (Figures 2 and 3).
[0217] Kinetic analysis of the trans-splicing reaction To determine the splicing rate of the trans-splicing reaction, data were fitted to a first-order rate equation using GraphPad Prism software.
number
[0218] where [P] is the product normalized intensity and [P] max is the reaction plateau, and k is the rate constant (s -1 ) The mean and standard error of each value are reported (n=3).
[0219] Expression of inteins for structural studies Cat with minimal extein sequence for structural characterization C Optimization of the construct was necessary to isolate AceL. Upon recombinant expression in E. coli (18°C, 16 h or 37°C, 3 h), *C and G.O.S. C Compared to SUMO-Cat C However, removal of the SUMO expression tag resulted in increased yields of Cat C Aggregation of Cat(II) occurred (presumably due to its neutral charge at physiological pH, pI = 7.2). Therefore, to improve the solubility of the protein in solution, C The SUMO-Flag-Cat was modified with charged residues, specifically, an N-terminal FLAG epitope tag and a “CESRGK” C-extein sequence (SUMO-Flag-Cat C ). The Cat N The construct was a SUMO fusion (SUMO-Cat N ) and contains the minimal "EFE" N-extein after SUMO cleavage. Additionally, we included inactivating C1A and N134A mutations in the construct to prevent splicing during structural analysis of the assembled complex. N and Cat C Expression and purification of the constructs was performed as described above for the proteins used for splicing.
[0220] Expression of isotopically enriched Cat protein for use in NMR spectroscopy was performed as previously described. The intein plasmid was transformed into BL-21(DE3) cells, and these cells were grown overnight (37°C, 18 h) in 5 mL LB starter cultures. The starter cultures were then spun down (4,000 rcf, 5 min). After discarding the supernatant, the cells were resuspended in 100 mL of LB as the sole carbon and nitrogen source. 13 C-glucose and 15 The cells were resuspended in 1 L of M9 medium (50 μg / mL kanamycin, 37 °C) supplemented with NH4Cl and grown at OD 600When the β-actin ATPase activity reached 0.6, expression was induced by addition of IPTG (0.5 mM, 18 h, 18°C). After expression, cells were spun down by centrifugation (5,000 rcf, 30 min) and stored at -80°C. Purification was performed using the general method described above for the intein constructs. The mass of purified protein was determined by the Cat N and Cat C This corresponds to an isotope labeling efficiency of 99% for both proteins.
[0221] NMR spectroscopy NMR experiments have demonstrated that Cat N and Cat C NMR samples were prepared by buffer exchange of the purified protein into 20 mM sodium phosphate, 150 mM NaCl, 2 mM TCEP (pH 6.8, 37 °C). 15 N, 13 C. 1 The H protein was concentrated to a final concentration of approximately 300-600 μM. For HSQC experiments of the complexes shown in Figure 3A and 3B, the isotopically labeled intein fragments were mixed with the complementary unlabeled intein solution in a 1:1.5 ratio, concentrated to a final concentration similar to that of the free protein, and measured directly. For structure determination, the isotopically labeled intein fragments were mixed with the complementary unlabeled intein solution in a 1.5:1 ratio of Cat N :Cat C The complex was further purified by size exclusion chromatography to remove the free form.
[0222] Experiments were performed at field strengths of 600, 700, 800 or 900 MHz, employing Non-Uniform Sampling (NUS) acquisition where appropriate. NMR spectra were processed using Bruker Topspin 3.0 or NMR Pipe software, and NUS spectra were reconstructed by compressed sensing using qMDD.
[0223] Chemical shift assignment Main chain chemical shifts were assigned using HNCO, HN(CA)CO, HNCACB, CBCA(CO)NH triple resonance experiments. Side chain assignments were obtained from H(CC)(CO)NH, (H)CC(CO)NH, H(C)CH-TOCY and (H)CCH-TOCSY experiments. Aromatic assignments were obtained from CT- 13 C decomposition [ 1 H, 1 H-NOESY (mixing time = 100 ms), (HB)CB(CGCD)HD and (HB)CB(CGCDCE)HE experiments. CcpNmr analysis software was used for manual chemical shift assignment and other data analysis. Chemical shift values were validated and deposited in the Biological Magnetic Resonance Bank (BMRB No: 30480). Random coil chemical shifts were calculated using CcpNmr analysis.
[0224] Measurement of spin relaxation 15 The spin-spin relaxation (R2) rates of N spins (mixing times 0, 17, 34, 51, 85, 119, 170, 255, 340, 510, and 680 ms) and [ 15 N- 1 [H]NOE experiments were performed at a field strength of 600 MH.
[0225] Structure determination Dihedral angle restraints were calculated from chemical shifts using the TALOS software. 13 The NOE cross peaks are 15 N decomposition [ 1 H, 1 H]-NOESY experiment (mixing time = 80 ms), 13 C decomposition [ 1 H, 1 H]-NOESY experiment (mixing time = 80 ms), CT- 13 C-decomposed aromatic [ 1 H, 1H]-NOESY experiments (mixing time = 100 ms) and were assigned automatically using ARIA and CNS software. The assignment and structure calculation were performed in eight cycles, with 20 structures calculated at each step. The assigned NOEs were manually confirmed and violation analysis was performed. Distance restraints were generated using the confirmed NOE peak list. Finally, 256 structures were calculated using 3,283 explicit restraints, 206 ambiguous restraints and 180 dihedral angle restraints. 20 minimum energy structures were selected and water refinement was performed. The structures were validated and deposited in the Protein Data Bank (PDB ID: 6DSL).
[0226] Circular dichroism (CD) Cat N , Cat C , and Cat N and Cat C The 1:1 complex was dialyzed against CD buffer (25 mM sodium phosphate, 50 mM NaF, 1 mM DTT, pH 7.2). CD spectra were measured in a 1 mm path length cuvette at 25°C (10 μM sample concentration).
[0227] Analytical Size Exclusion Chromatography (SEC) Analytical SEC experiments were performed on an S75 10 / 300 column at 4° C. in splicing buffer (25 mM sodium phosphate, 150 mM NaCl, 1 mM DTT, pH 7.2). For all analyses, UV absorbance was monitored at 214 nm. Samples were injected in a sample volume of 500 μL (25 μM) and eluted at a flow rate of 0.5 mL / min.
[0228] Limited proteolysis EFE-Cat N , Flag-Cat C , and EFE-Cat N and Flag-Cat CThe 1:1 complex of was dialyzed against thermolysin buffer (50 mM Tris HCl, 100 mM NaCl, 2 mM MgSO4, 2 mM CaCl2, 1 mM DTT, pH 7.4) and diluted to a concentration of 10 μM. Thermolysin powder (Sigma) was prepared at 0.4 mg / mL in thermolysin buffer and added to each solution (1:50 v / v). At the indicated time points, aliquots were removed and quenched by the addition of 8 M guanidine HCL 4% TFA at a ratio of 1:3. These samples were then analyzed by RP-HPLC and ESI-MS. The mass from each peak was compared to the putative cleavage products of the intein obtained from ProteinProspector (UCSF).
[0229] Production of inteins for conjugation experiments Fluorescein-labeled Cat N (Fl-Cat N The Fl-Cat peptide was synthesized by standard 9-fluorenylmethyl-oxycarbonyl (Fmoc) solid-phase peptide synthesis (SPPS). After coupling of the last amino acid of the peptide, the N-terminus was capped with 5(6)-carboxyfluorescein. N Peptides were purified by preparative RP-HPLC and characterized by analytical RP-HPLC and ESI-MS. The C-intein expressed for binding experiments was the SUMO-Flag-Cat C Instead of performing Ulp1 digestion, the expressed SUMO-Flag-Cat C The protein was purified directly on a S75 16 / 60 gel filtration column after Ni-NTA concentration.
[0230] Steady-state fluorescence anisotropy Equilibrium measurements were performed using a given concentration of SUMO-Flag-Cat in low-salt buffer (50 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.0) and high-salt buffer (50 mM sodium phosphate, 500 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.0). C(0pM~2,500pM) with 500pM Fl-Cat N Proteins were diluted from stock solutions to the desired concentrations and incubated at 25°C for 30 min. Samples were transferred to 1 cm path length cuvettes and fluorescence anisotropy was measured immediately. Constants for the one-site binding equation were obtained using a nonlinear least-squares curve fitting method in MATLAB. The constants obtained from these fits (Table 4) in both high and low salt conditions were consistent with the CatAb used for the measurements. N Therefore, the inventors concluded that the lower concentration of Cat N Since it was not possible to measure the fluorescence anisotropy at K d is reported as <500 pM.
[0231] [Table 4]
[0232] Stopped-flow fluorescence anisotropy Stop flow syringe with Fl-Cat N and SUMO-Flag-Cat C Protein solution was diluted to a final concentration of 100 nM Cat N and Cat at the indicated concentrations. C The anisotropy was measured for 50 seconds in low-salt and high-salt buffers. The time course of anisotropy was fitted to a previously reported biexponential kinetic model using a nonlinear least-squares curve fitting method in MATLAB to obtain the binding rate constant (k obs1 and k obs2 ) was obtained. 16 Next, k obs1 value and k obs2 Value Cat C Plot as a function of concentration, fit a line, and define the slope of the line as k on This is what I interpreted.
[0233] result 1. Design of consensus atypical split inteins with enhanced stability and activity To determine the mechanism of fragment assembly, an atypical split intein with minimal extein residues was isolated. Both naturally occurring atypical split inteins whose splicing rates were characterized in vitro were identified within the T4-bacteriophage-type DNA packaging terminase large subunit (TerL) from metagenomic sequencing data. The first one (AceL), from the saline meristem Lake AceL in Antarctica, exhibits an optimal splicing rate at 8 °C (t1 / 2 = 7 min). Furthermore, directed evolution led to the identification of stabilizing mutations within AceL (AceL) that increase activity at 37 °C (t1 / 2 = 6 min). * The second characterized atypical split intein was sequenced in a sample taken from Punta Cormorant during the Global Ocean Sampling Project (GOS) and splices at an optimum temperature of 30°C (t1 / 2 = 3 min). Soluble GOS from expression in E. coli N (i.e., N-terminal GOS intein fragment), GOS C , or AceL *C Purification of the atypical split intein was achieved by the large stabilized extein protein (Figure 4). Extraction of the atypical split intein lacking the solubilized extein from the insoluble inclusion body fraction using chaotropic agents was unsuccessful due to aggregation problems upon refolding.
[0234] Consensus design, a protein engineering strategy that uses evolutionary information from homologous protein sequences to predict stabilizing mutations, has been previously applied to create a highly active, thermostable, naturally occurring split DnaE intein (Cfa). In an effort to generate an atypical split intein suitable for in vitro structural characterization, TerL, discovered from a BLAST search of metagenomic sequencing information in the JGI and NCBI databases, was used to generate a stabilizing mutation in the TerL intein. N and TerL CA consensus atypical (Cat) TerL intein was designed from a multiple sequence alignment (MSA) of inteins (Table 1). N (60%) and Cat C (64%) for both AceL *N and AceL *C Cat intein pairs were isolated and fused to model exteins to measure their in vitro trans-splicing activity (Table 5). Cat exhibited ultrafast splicing activity (t 1 / 2 =59s), AceL was consistently observed across a range of temperatures. * (Figure 5). Furthermore, Cat has * PTS was also measured in the presence of chaotropic agents that are commonly used to solubilize aggregation-prone extein fragments. 1Cat showed enhanced chaotropic stability and was able to splice in both 2M and 4M urea (Figure 5, Table 6), whereas AceL * is inactive under both of these conditions. The accelerated splicing rate and activity under adverse conditions establish Cat as the fastest and most robust atypical split intein reported to date and should therefore serve as a tool for synthetic N-terminal modification of proteins.
[0235] [Table 5]
[0236] [Table 6]
[0237] 2. Assembly of fragments induces a structural transition from disorder to order To investigate the assembly process of atypical split inteins, we used Cat N and Cat C isotope enrichment medium (15 N, 13 The constructs were expressed in situ in vitro (C), purified, and analyzed by nuclear magnetic resonance (NMR) spectroscopy. Note that these constructs also contained the inactivating C1A and N134A mutations to prevent splicing during structural analysis of the complex. N of 1 H- 15 The N HSQC spectrum is 1 It shows minimal variance in the H dimension, a phenomenon common to disordered proteins, and is C and Npu C This has been observed in the past (Figure 6). C When added, Stark transition occurs and well-dispersed 1 H- 15 N HSQC spectrum is obtained, which is N This is consistent with the fold of Cat N In 1 H- 15 Measurements of N heteronuclear NOEs, spin-spin relaxation rates, and Cα-Cβ chemical shift perturbations reveal that Cat C When combining, Cat N Further evidence of the disorder-to-order transition of Cat C of 1 H- 15 N HSQC showed far fewer crosspeaks than would be expected given the number of residues in the protein, a feature present in dynamic proteins undergoing chemical exchange, as previously seen for both SspN and NpuN (Figure 6). N Addition of Cat resulted in the appearance of new cross peaks, indicating a transition to a more ordered complex (Figure 6). C Although the quality of the spectra did not allow us to assign proteins, some cross-peaks overlapped with those seen in the bound form, suggesting that the free and bound forms of Cat C suggests that they share partial structural identity.
[0238] In agreement with the NMR studies, analysis by circular dichroism spectroscopy revealed that the unbound Cat N tends to extract secondary structures and is less structured, whereas Cat N and Cat C We show that both inteins undergo a conformational transition upon association (Figure 6). C Further evidence of folding upon binding was obtained by size-exclusion chromatography (SEC), as Cat elutes faster than the bound complex despite having a smaller molecular weight (Figure 6). The SEC elution profile shows that Cat elutes faster than the bound complex when its cognate intein is bound. C This is consistent with the compression of
[0239] 3. Solution structure of an atypical split intein complex Isotopically enriched Cat N and Cat C The protein was assembled into a complex and its structure was calculated from distance and dihedral angle restraints obtained from NMR spectroscopy. The 20 lowest energy conformers obtained from the structure calculation are shown (Figure 8A, PDB ID: 6DSL). This structural ensemble includes all regions of the protein (Cat C The results are accurate across the entire protein (excluding short solubility tags within exteins and exteins) with an average backbone RMSD of 1.19 Å for the average structure (Table 7). Residual backbone RMSD values of <0.5 Å were obtained in structured regions of the protein (Figures 9A and 9B). The structure of Cat is primarily β-sheet, with Cat N The last eight residues at the C-terminus of are the only α-helix (Figure 8). It has a horseshoe structure typical of proteins containing HINT domains. The structure of Cat is similar to that of DnaE inteins such as Npu (PDB ID: 2KEQ, RMSD 1.45 Å over 92 aligned Cα atoms) and Ssp (PDB ID: 1ZDE, RMSD 1.34 Å over 90 aligned Cα atoms) (except that Npu and Ssp have an additional helix that is absent in Cat).
[0240] In the Cat active site, a serine residue (Ser75 ) replaces the threonine located in the canonical TXXH B-block motif (Figure 9C). The carbonyl oxygen of C1A is in close proximity to the amide (2.4 Å) and hydroxyl (3.7 Å) protons of Ser75 (Figure 8C). The threonine residues in DnaE intein adopt a similar conformation, suggesting that Ser75 serves as a threonine assisting in cleavage of the N-terminal scissile peptide bond. Another notable feature of the structure is the lack of an F-block histidine (Figure 9C), and thus resolution of branched intermediates may be mediated by the penultimate G-block histidine (His133). [Table 7]
[0241] 4. Mapping localized disorder in cats To examine the distribution of local structures in Cat, limited proteolysis by thermolysin digestion was applied (Figure 10A). N undergoes rapid decomposition, whereas Cat C shows somewhat greater resistance to proteolysis. However, the intein complex remained intact after 30 min. The observed variation in protease sensitivity was mostly due to the disordered Cat N , partially disordered Cat C , and is consistent with the formation of a globular fold upon binding. We next examined the cleavage products (t = 30 min) using electrospray ionization mass spectrometry (ESI-MS) to determine regions protected from proteolysis, which should represent localized structural elements (Figure 11, Table 8). N In Cat, the cleavage sites appear to be uniformly distributed throughout the primary sequence. CMost of the Cat protein is resistant to proteolysis. Many peaks corresponding to intact fragments centered around residues 57–112 are observed, pointing to this region as a structured region flanked by disordered N- and C-terminal peptides (Fig. S10B). Mapping this model onto the structure of Cat reveals that Cat C The N-terminus and C-terminus of N In addition, the key catalytic residues for succinimide formation (Asp115, His133, and Asn) are shown to directly interact with the ribosomal carboxyl group (Figure 10C). 134 ) is a Cat C It exists within the disordered region of
[0242] [Table 8]
[0243] 5. Assembly is primarily driven by hydrophobic interactions After examining the structural characteristics of the Cat fragments in their split form, we sought to identify the molecular components that mediate their assembly. N and Cat C The primary sequence of Cat shows charge separation, but N -Cat C The binding surface of Cat is rich in hydrophobic residues (Figures 12A and B). N and Cat C Both charged residues of Cat(II) are excluded towards the exterior of the protein, whereas hydrophobic residues cluster at the binding interface (Figure 13A and B). To confirm that these hydrophobic interactions drive the formation of the complex, the effect of buffer ionic strength on fragment association was assessed using a fluorescence anisotropy-based binding assay. Cat(II) containing an N-terminal fluorescein N (Fl-Cat N ) was synthesized by solid-phase peptide synthesis and SUMO-Cat C We observed an increase in fluorescence anisotropy upon association with the fusion protein (Figure 12C). NThe expected increase in rotational correlation time of the Cat complex compared to the Cat complex was used as a measure of Cat complex formation. As with other split inteins, Cat N and Cat C displayed high binding affinity in vitro, with K values below 500 pM, which was the detection limit of the assay (Table 9). Importantly, the binding isotherm for Cat complex formation was perturbed at least by changes in buffer ionic strength, consistent with an association process driven by hydrophobic interactions.
[0244] Next, Fl-Cat N and SUMO-Cat C The kinetics of binding between kon1 and kon2 were monitored by stopped-flow fluorescence, and the data were found to be best fitted to a double exponential model (Figure 13C). Both determined rate constants (kobs1 and kobs2) showed concentration dependence, with calculated values of kon1 (2.80 ± 0.28) × 106 M-1 s-1 and kon2 (0.16 ± 0.019) × 106 M-1 s-1 under low salt conditions, and kon1 (2.34 ± 0.30) × 106 M-1 s-1 and kon2 (0.18 ± 0.016) × 106 M-1 s-1 under high salt conditions (Figure 12D, Table 4). This model suggests that parallel association events may proceed from different conformers of the intein, and that a subset of conformers is kinetically distinguishable. Furthermore, both kobs1 and kobs2 were significantly higher than all measured Cat C The finding that concentration is not perturbed by buffer ionic strength further suggests that the association is driven primarily by hydrophobic interactions.
[0245] [Table 9]
[0246] 6.Cat extein dependency To date, all inteins characterized show splicing rates that depend on the adjacent extein residues. Deviations from the native extein sequence often slow down splicing, which may limit the application of PTS. Since the extein dependency of TerL inteins has not yet been fully characterized, we sought to identify the sequence preference of Cat by introducing substitutions that differ in charge and steric bulk from the native residues (Figure 14A). Substitutions of Cys+1, Glu+2, and Phe+3 from the native C-extein were introduced at positions +2 and +3 and assayed in vitro (Figure 14B, Table 10). Cat shows remarkable C-extein promiscuity, splicing with a half-life ranging from 1 to 3 minutes. This broad tolerance of C-extein substitutions is even better than engineered versions of Npu that were previously designed to have promiscuous activity. In contrast to this tolerance to C-extein substitutions, Cat shows a Stark dependency on the identity of the -1 residue, with loss of activity resulting from the insertion of alanine (t1 / 2 = 54 min), glycine (t1 / 2 = 146 min), or proline (t1 / 2 = 158 min) at this position (Figure S14C, Table 10). The assessed in vitro extein dependency is likely explained by interactions seen in the solution structure of the Cat complex. Both Glu+2 and Phe+3 appear to make minimal contacts with the active site catalytic residues, consistent with the experimentally observed C-extein promiscuity (Figure S14D). Interestingly, Glu+2 makes contact with Asn123, which resides in place of an F-block histidine. In contrast, Glu-1 directly interacts with two conserved residues involved in thioester formation, Ser75 and His78 (Figure S14E). Thus, the N-extein substitution may directly interfere with the protein splicing catalytic ability of Ser75 and His78.
[0247] [Table 10]
Claims
1. A split intein N-terminal fragment comprising the amino acid sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1, which variant maintains or improves the ability to catalyze the N-terminal cleavage of SEQ ID NO:1 and / or its trans-splicing activity.
2. 2. The split intein N-fragment of claim 1, wherein the variant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-6, 125-127 and 168-170.
3. 3. The split intein N-fragment of claim 2, wherein the functionally equivalent variant comprises the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO:
125.
4. (i) a compound of interest, and (ii) A split intein N-fragment according to claim 1, or a split intein N-fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. A complex comprising: The conjugate optionally comprises a linker between (i) and (ii); the compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the N-terminus of the split intein N-fragment by an amide bond. Complex.
5. 5. The complex of claim 4, wherein the split intein N-fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-68 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NOs: 49-68, which variant maintains or improves their ability to catalyze N-terminal cleavage and / or their trans-splicing activity.
6. 6. The complex of claim 4 or 5, wherein the target compound is a polypeptide or protein, an antibody, or a fragment of a protein, and the complex comprises a linker, the linker being a peptide linker.
7. A split intein C-terminal fragment comprising the amino acid sequence set forth in SEQ ID NO:7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO:7 over the entire length of the sequence, which variant maintains or improves the ability to catalyze the C-terminal cleavage of SEQ ID NO:7 and / or its trans-splicing activity.
8. 8. The split intein C-fragment of claim 7, wherein the variant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-48 and 128-166.
9. 9. The split intein C-fragment of claim 8, wherein the functionally equivalent variant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-22 and 128-140.
10. (i) a split intein C-fragment according to any one of claims 7 to 9 or comprising a sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and (ii) Target compound A complex comprising: The conjugate optionally comprises a linker between (i) and (ii); the compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond. Complex.
11. 11. The complex of claim 10, wherein the split intein C-fragment comprises a sequence selected from SEQ ID NOs: 69-87 or a functionally equivalent variant thereof having at least 90% sequence identity to SEQ ID NOs: 69-87, which variant maintains or improves their ability to catalyze C-terminal cleavage and / or their trans-splicing activity.
12. The conjugate of claim 11, wherein the target compound is a polypeptide or protein, an antibody, or a fragment of a protein, and the conjugate comprises a linker, the linker being a peptide linker.
13. (i) a split intein C-fragment according to any one of claims 7 to 9 or a split intein C-fragment comprising a sequence selected from the group consisting of SEQ ID NOs: 114 to 120; (ii) a compound of interest, and (iii) A split intein N-fragment according to any one of claims 1 to 3 or comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110. A complex comprising: the conjugate optionally comprises a linker between (i) and (ii) and / or between (ii) and (iii); the compound of interest is linked to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond; the compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the N-terminus of the split intein N-fragment by an amide bond. Complex.
14. A composition comprising the complex of claim 4 and the complex of claim 10.
15. A conjugate comprising the complex of claim 4 and the complex of claim 10, wherein the C-terminus of the split intein N-fragment is linked to the N-terminus of the split intein C-fragment by a peptide bond.
16. (a) a complex according to claim 6, and (b) a split intein C-terminal fragment comprising an amino acid sequence as set forth in SEQ ID NO: 7, a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120. A conjugate comprising the C-terminus of the split intein N-fragment is linked to the N-terminus of the split intein C-fragment by a peptide bond; Conjugate.
17. Select from the following: (i) a split intein N-fragment according to claim 1, or A complex according to claim 6, or A split intein C-fragment according to claim 7, or A complex according to claim 12, or 14. The conjugate of claim 13, wherein the target compound is a protein and the conjugate comprises a linker, the linker being a peptide linker; or The conjugate of claim 16. or a polynucleotide encoding (ii) a vector comprising the polynucleotide of (i); or (iii) a host cell comprising the polynucleotide of (i) or the vector of (ii).
18. A method for obtaining a conjugate between a first compound of interest and a second compound of interest, the method being selected from the following methods: (A) A method comprising: (i) (a) a first compound of interest and a split intein N-terminal fragment comprising an amino acid sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1, which maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NOs:103-110. and, (b) a complex according to claim 10 comprising a second compound of interest and the amino acid sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120; or A complex comprising an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with the AceL-TerL split intein C-terminal fragment and maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, and a second compound of interest, Optionally, comprising a linker between the split intein C-fragment and the second compound of interest; the second compound of interest is attached to the C-terminus of the split intein C-fragment by an amide bond; or When the conjugate comprises a linker, the second compound of interest is attached to the linker by an amide bond and / or the linker is attached to the C-terminus of the split intein C-fragment by an amide bond; Complex And, contacting the split intein N-fragment and the split intein C-fragment under suitable conditions to combine to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between a first compound of interest and a second compound of interest; and (B) A method comprising: (i) (a) a complex according to claim 4 comprising a first compound of interest and the amino acid sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1, which variant maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a split intein N-fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:103-110; or A complex comprising a second compound of interest and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, said variant having at least 90% sequence identity with said AceL-TerL split intein N-terminal fragment and maintaining or improving its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, Optionally, comprising a linker between the compound of interest and the split intein N-fragment; the compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is bound to the linker by an amide bond and / or the linker is bound to the N-terminus of the split intein N-fragment by an amide bond. and, (b) a second compound of interest and a functionally equivalent variant thereof having an amino acid sequence of SEQ ID NO: 7 or at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 114-120. And, contacting the split intein N-fragment and the split intein C-fragment under suitable conditions to combine to form an intein intermediate; and (ii) reacting the intein intermediate to form a conjugate between a first compound of interest and a second compound of interest.
19. A method for obtaining a conjugate of a target compound and a nucleophile, comprising the steps of: (i) (a) the conjugate according to claim 4, wherein the split intein N-fragment comprises the amino acid sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO: 1, which variant maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110; or 1. A complex comprising a compound of interest and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, said variant having at least 90% sequence identity with said AceL-TerL split intein N-terminal fragment and maintaining or improving its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, Optionally, comprising a linker between the compound of interest and the split intein N-fragment; the compound of interest is linked to the N-terminus of the split intein N-fragment by an amide bond; or When the conjugate comprises a linker, the compound of interest is attached to the linker by an amide bond and / or the linker is attached to the N-terminus of the split intein N-fragment by an amide bond; Complex and, (b) a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 9, 23-48, and 141-166. And, contacting under suitable conditions to allow binding between the split intein N-fragment and the split intein C-fragment to form an intein intermediate; and (ii) contacting the intein intermediate with an exogenous nucleophile. The method comprising:
20. (a) from the N-terminus to the C-terminus: a first polypeptide of interest, and a split intein N-fragment comprising the sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1, which variant maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO:103 to 110 a first polynucleotide encoding a first fusion protein comprising: (b) from the N-terminus to the C-terminus: - an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL split intein C-terminal fragment and maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (c) from the N-terminus to the C-terminus: a first polypeptide of interest, and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL split intein N-terminal fragment and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof, which has at least 90% sequence identity with SEQ ID NO: 1 and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110 a first polynucleotide encoding a first fusion protein comprising: (d) from the N-terminus to the C-terminus: - a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO: 114-120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising A composition comprising:
21. A method for expressing a gene of interest in a cell, the method being selected from the following methods: (A) A method comprising: (i) the cell (a) from the N-terminus to the C-terminus: a first polypeptide of interest, and a split intein N-fragment comprising the sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1 and which maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO:103 to 110 a first polynucleotide encoding a first fusion protein comprising: (b) from the N-terminus to the C-terminus: - an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL split intein C-terminal fragment and maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising: or, (c) from the N-terminus to the C-terminus: a first polypeptide of interest, and an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL split intein N-terminal fragment and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof, which has at least 90% sequence identity with SEQ ID NO: 1 and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110 a first polynucleotide encoding a first fusion protein comprising: (d) from the N-terminus to the C-terminus: - a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO: 114-120, and A second polypeptide of interest A second polynucleotide encoding a second fusion protein comprising contacting the (ii) expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced; and (iii) contacting the first fusion protein with the second fusion protein such that the split intein N-fragment binds to the split intein C-fragment to form an intein intermediate, and such that the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest and the N-terminus of the second polypeptide of interest; (B) A method comprising: (i) a first cell; From the N-terminus to the C-terminus a first polypeptide of interest, and a split intein N-fragment comprising the sequence of SEQ ID NO:1 or a functionally equivalent variant thereof having at least 90% sequence identity with SEQ ID NO:1, which variant maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO:103 to 110 a first polynucleotide encoding a first fusion protein comprising a signal peptide; and (ii) subjecting the second cell to, in an N-terminus to C-terminus - an AceL-TerL split intein C-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL split intein C-terminal fragment and maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or a split intein C-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 114 to 120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising a signal peptide; contacting the or, (iii) dividing the first cell into two portions, from the N-terminus to the C-terminus, a first polypeptide of interest, and - an AceL-TerL split intein N-terminal fragment or a functionally equivalent variant thereof, which has at least 90% sequence identity with said AceL-TerL and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a sequence of SEQ ID NO: 1 or a functionally equivalent variant thereof, which has at least 90% sequence identity with SEQ ID NO: 1 and maintains or improves its ability to catalyze N-terminal cleavage and / or its trans-splicing activity, or a split intein N-terminal fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 103 to 110 a first polynucleotide encoding a first fusion protein comprising a signal peptide; and (iv) a second cell; From the N-terminus to the C-terminus, - a split intein C-terminal fragment comprising the sequence of SEQ ID NO: 7 or a functionally equivalent variant thereof having at least 88% sequence identity with SEQ ID NO: 7 over the entire length of the sequence, which variant maintains or improves its ability to catalyze C-terminal cleavage and / or its trans-splicing activity, or an amino acid sequence selected from the group consisting of SEQ ID NO: 114-120, and A second polypeptide of interest a second polynucleotide encoding a second fusion protein comprising a signal peptide; contacting the (v) expressing the first polynucleotide and the second polynucleotide such that the first fusion protein and the second fusion protein are produced and secreted; and (vi) contacting the first fusion protein with the second fusion protein such that the split intein N-fragment binds to the split intein C-fragment to form an intein intermediate, and such that the intein intermediate reacts to covalently link the C-terminus of the first polypeptide of interest and the N-terminus of the second polypeptide of interest.
Citation Information
Patent Citations
Atypical inteins
WO2015086825A1
